## Stereoselective synthesis of 3-oxo-2-C-branched glycosides from 2,3-

## unsaturated sugars via [3,3] sigmatropic rearrangement

Intzar Ali, Sravani Gundumalla and Ramu Sridhar Perali\*

e-mail: p\_ramu\_sridhar@uohyd.ac.in

## **Table of Contents**

1.	General Information	2
2.	General procedures	2
3.	Iodo-acetalyzation of glycals (General Procedure A)	2
4.	Dehydrohalogenation-synthesis of vinyl ether (General procedure B)	2
5.	[3,3] sigmatropic rearrangement (General procedure C)	2
6.	General procedure for 3-O-alkylation of	
	glycal derivative (General Procedure D)	3
7.	Experimental procedures and spectral data	3-36
8.	NMR Spectra	37-167

## **General Information:**

All the reactions were carried out under nitrogen or argon atmosphere and monitored by thin layer chromatography (TLC) using silica gel GF<sub>254</sub> plates with detection by charring with 5% (v/v) H<sub>2</sub>SO<sub>4</sub> in methanol or by phosphomolybdic acid (PMA) stain or by ultraviolet (UV) detection. All the chemicals were purchased from Sigma-Aldrich or TCI Chemical Company. Solvents used in the reactions were distilled over dehydrated agents. Silica-gel (100-200 mesh) was used for column chromatography. <sup>1</sup>H, <sup>13</sup>C, DEPT, COSY, and NOESY spectra were recorded on Bruker 400 MHz or 500 MHz spectrometer. <sup>1</sup>H NMR chemical shifts were reported in ppm ( $\delta$ ) with TMS as internal standard ( $\delta$  0.00) and <sup>13</sup>C NMR were reported in chemical shifts with solvent reference (CDCl<sub>3</sub>,  $\delta$  77.00). High resolution mass spectra (HRMS) were recorded on Bruker maXis ESI-QTOF spectrometer.

## **General Procedures:**

#### 2.1 Iodo-acetalyzation of glycals (General Procedure A):

To a stirred solution of protected glycal in acetonitrile (10 mL/mmol) under inert atmosphere was added benzyl alcohol (5 eq) followed by *N*-iodosuccinimide (1.5 eq) at 0 °C. The reaction was allowed to room temperature and stirred until starting material is disappeared. The reaction was quenched with saturated solution of sodium thiosulphate and extracted with EtOAc. The combined organic layer was dried over anhydrous  $Na_2SO_4$  and concentrated under reduced pressure. The obtained crude product was purified by silica gel column chromatography using hexanes and ethyl acetate to give pure 2-deoxy 2-iodo glycoside.

#### 2.2 Dehydrohalogenation-synthesis of vinyl ether (General procedure B):

To a stirred solution of 2-deoxy 2-iodo glycoside in toluene (10 mL/mmol) under inert atmosphere was added DBU (1.1 eq) at room temperature. The reaction mass was heated at 80 °C for 24 h. After complete conversion of starting material (monitored by TLC), solvent was removed under reduced pressure to obtain crude product which was purified over basic alumina using hexanes and ethyl acetate to obtain vinyl ether.

#### 2.3 [3,3] sigmatropic rearrangement (Claisen rearrangement) (General procedure C):

Vinyl glycoside (2.4 mmol, 1 equiv.) was mixed with *N*,*N*-dimethylaniline (0.2 mL) in nitrobenzene (10 mL), and the mixture was heated at 150–170  $^{\circ}$ C until the starting material was completely consumed (5–6 h). The resulting mixture was instantly loaded onto a silica gel

column, and the product was purified by eluting with hexanes and ethyl acetate to obtain the 3-oxo-2-*C*-branched glycoside derivative.

**2.4 General procedure for 3-***O***-alkylation of glycal derivative (General Procedure D):** The 3-hydroxy glycal was dissolved in anhydrous THF (3 mL/mmol) under an inert atmosphere and the mixture was cooled to 0 °C. NaH (1.5 eq, 60%) was added portion-wise with stirring over a period of 20 minutes. After continued stirring for a further 1 hour at 0 °C, alkyl halide (1.25 eq) and TBAI (0.1 eq) were added at 0 °C and the mixture was stirred overnight at 25 °C. After completion of the reaction (monitored by TLC) cold water was added dropwise and the obtained solution was extracted with ethyl acetate. The combined organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain the crude alkyl protected glycal derivative that was purified by silica gel column chromatography using hexanes and ethyl acetate to give pure 3-*O*-alkylated glycal derivative.

## Experimental procedures and spectral data:



(2S,3S,4S,5R,6R)-2,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)-3-iodotetrahydro-2H-

**pyran (5):** Compound **5** was synthesized from tribenzyl D-glucal **4**<sup>1</sup> (1 g, 2.40 mmol) by following general **procedure A.** 

Yield: 1.43 g, 92 % colourless gel.  $R_f = 0.5$  (10% EtOAc/hexane).

<sup>1</sup>**H NMR (500 MHz, CDCl<sub>3</sub>):** δ 7.30-7.44 (m, 20H), 5.46 (s, 1H), 4.88-4.92 (m, 1H), 4.78 (d, 1H, *J* = 15.0 Hz), 4.75 (s, 1H), 4.72 (s, 1H), 4.58-4.61 (m, 2H), 4.53-4.56 (d, 2H), 4.51 (d, 1H, *J* = 15.0 HZ), 3.97-3.99 (m, 2H), 3.83-3.86 (m, 1H), 3.75 (8, 1H, *J*= 13.5 Hz), 3.40-3.43 (m, 1H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 138.3, 138.1, 137.6, 136.8, 128.4, 128.3, 128.3, 128.2, 128.0, 128.0, 127.9, 127.9, 127.7, 127.6, 127.6, 127.4, 100.6, 76.7, 75.8, 75.2, 73.3, 72.3, 70.9, 69.4, 68.7, 33.4.

HRMS (ESI-TOF) *m/z*: [M+NH<sub>4</sub>] calcd for C<sub>34</sub>H<sub>35</sub>IO<sub>5</sub>NH<sub>4</sub> 668.1873, found 668.1871



### (2*R*,3*R*,6*S*)-3,4,6-tris(benzyloxy)-2-((benzyloxy)methyl)-3,6-dihydro-2*H*-pyran (6):

Compound **6** was synthesized from **5** (1 g, 1.53 mmol) by following **general procedure B.** Yield: 771.1 mg, 96%, colorless gel.  $R_f = 0.4$  (10% EtOAc/hexane).  $[\alpha]_D^{25} = 126.1$  (*c* 0.98, CHCl<sub>3</sub>).

<sup>1</sup>**H NMR (500 MHz, CDCl<sub>3</sub>):**  $\delta$  7.27-7.41 (m, 20H), 5.36 (d, 1H, *J* = 4.5 Hz), 4.88-4.96 (m, 3H), 4.81 (t, 2H, *J* = 16.0 Hz), 4.67 (d, 1H, *J* = 15.5 Hz), 4.63 (d, 1H, *J* = 14.5 Hz), 4.52 (d, 1H, *J* = 15.0 Hz), 4.47 (d, 1H, *J* = 14.0 Hz), 4.34 (d, 1H, *J* = 12.0 Hz), 4.21- 4.25 (m, 1H), 3.72-3.76 (m, 1H), 3.64 (dd, 1H, *J*<sub>1</sub> = 2.5, *J*<sub>2</sub> = 27 Hz ).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 158.0, 138.2, 138.2, 138.1, 136.4, 128.4, 128.3(2), 128.2, 128.1, 128.0, 127.9, 127.9, 127.6, 127.6, 127.6, 127.5, 95.8, 95.4, 74.1, 73.3, 71.1, 69.8, 69.7, 69.4, 68.6

HRMS (ESI-TOF) m/z: [M+NH4] calcd for C34H34O5NH4 540.2750, found 540.2755



(2R,3R)-3-(benzyloxy)-2-((benzyloxy)methyl)-2,3-dihydro-4H-pyran-4-one (3):

Compound **3** was synthesized from **6** (500 mg, 0.95 mmol) by following general **procedure C.** Yield: 139.6 mg, 45%, colorless gel.  $R_f = 0.6$  (15% EtOAc/hexane).

<sup>1</sup>**H NMR (500 MHz, CDCl<sub>3</sub>):**  $\delta$  7.28-7.35 (m, 11H), 5.38 (d, 1H, *J* = 6.0 Hz), 5.07 (d, 1H, *J* = 11.0 Hz), 4.57-4.61 (m, 2H), 4.52 (d, 1H, *J* = 12.0 Hz), 4.43 (dt, 1H, *J* = 3.0 Hz, 11.5 Hz), 4.24 (d, 1H, *J* = 12.0 Hz), 3.80 (m, 2H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 193.5, 162.2, 137.5, 137.4, 128.5, 128.4, 128.3, 128.0, 127.9, 127.8, 105.2, 81.0, , 74.6, 74.1, 73.6, 67.9.

HRMS (ESI-TOF) m/z: [M+H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>20</sub>O<sub>4</sub>H 325.1431, found 325.1431.



(2R,3S,4R)-4-(allyloxy)-3-(benzyloxy)-2-((benzyloxy)methyl)-3,4-dihydro-2H-pyran (10):

Compound **10** was synthesized from **9**<sup>2</sup> (500 mg, 1.53 mmol) by following general **procedure D.** Yield: 505.2 mg, 90%, colorless gel.  $R_f = 0.8$  (10% EtOAc/hexane).  $[\alpha]_D^{25} = 56.8$  (*c* 0.25, CHCl<sub>3</sub>).

<sup>1</sup>**H NMR (500 MHz, CDCl<sub>3</sub>):**  $\delta$  7.28-7.36 (m, 10H), 6.43 (dd, 1H, J = 0.5 Hz, J = 6.0 Hz), 5.90-5.98 (m, 1H), 5.31 (dd, 1H, J = 1.5 Hz, J = 17.0 Hz), 5.20 (dd, 1H, J = 1.5 Hz, J = 10.5 Hz), 4.85-4.87 (m, 2H), 4.67 (d, 1H, J = 11.5 Hz), 4.62 (d, 1H, J = 12.0 Hz), 4.58 (d, 1H, J = 12.0 Hz), 4.12-4.16 (m, 2H), 4.03-4.09 (m, 2H), 3.83- 3.84 (m 1H), 3.79-3.81 (m, 2H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 144.6, 138.2, 138.0, 134.8, 128.4, 128.3, 127.9, 127.8, 127.7, 127.6, 116.8, 100.1, 76.7, 75.7, 74.3, 73.7, 73.5, 69.4, 68.5.

HRMS (ESI-TOF) m/z: [M+Na] calcd for C<sub>23</sub>H<sub>26</sub>O<sub>4</sub>Na 389.1729, found 389.1724



(2S,3S,4S,5R,6R)-4-(allyloxy)-2,5-bis(benzyloxy)-6-((benzyloxy)methyl)-3-

iodotetrahydro-2*H*-pyran (11): Compound 11 was synthesized from 10 (300 mg, 0.81 mmol) by following general procedure A. Yield: 442.5 mg, 90%, colorless gel.  $R_f = 0.8$  (10% EtOAc/hexane).  $[\alpha]_D^{25} = 37.3$  (*c* 0.55, CHCl<sub>3</sub>).

<sup>1</sup>**H NMR** (**500 MHz**, **CDCl**<sub>3</sub>):  $\delta$  7.24-7.7.40 (m, 15H), 5.94-6.00 (m, 1H), 5.37 (d, 1H, J = 17.5 Hz), 5.33 (s, 1H), 5.22 (d, 1H, J = 10.0 Hz), 4.89 (d, 1H, J = 11.0 Hz), 4.74 (d, 1H, J = 12.0 Hz), 4.70 (d, 1H, J = 11.5), 4.49-4.58 (m, 4H), 4.18 (dd, 1H, J = 5.5 Hz, J = 12.5 Hz), 4.04 (dd, 1H, J = 5.5 Hz, J = 13.0 Hz), 3.89-3.95 (m, 2H), 3.80 (dd, 1H, J = 3.5 Hz, J = 10.5 Hz), 3.71 (d, 1H, J = 10.5 Hz), 3.26-3.29 (m, 1H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ, 138.4, 138.2, 136.9, 134.3, 128.4, 128.3, 128.3, 128.1, 128.0, 128.0, 127.7, 127.6, 127.4, 117.3, 100.7, 76.7, 76.0, 75.2, 73.4, 72.4, 70.0, 69.5, 68.9, 33.7.
HRMS (ESI-TOF) *m/z*: [M+Na]<sup>+</sup> calcd for C<sub>30</sub>H<sub>33</sub>IO<sub>5</sub>Na 623.1265, found 623.1266



# (2*R*,3*R*,6*S*)-4-(allyloxy)-3,6-bis(benzyloxy)-2-((benzyloxy)methyl)-3,6-dihydro-2*H*-pyran (12): Compound 12 was synthesized from 11 (300 mg, 0.49 mmol) by following general procedure B. Yield: 219.5 mg, 93%, colorless gel. $R_f = 0.7$ (10% EtOAc/hexane).

<sup>1</sup>**H NMR** (**500 MHz, CDCl<sub>3</sub>**):  $\delta$  7.27-7.7.38 (m, 15H), 5.98-6.0 (m, 1H), 5.37-5.41 (m, 1H), 5.32 (d, 1H, *J* = 3.5 Hz), 5.26-5.29 (m, 1H), 4.92 (d, 1H, *J* = 11.0 Hz), 4.82 (d, 1H, *J* = 3.5 Hz), 4.80 (d, 1H, *J* = 12.0 Hz), 4.65 (d, 1H, *J* = 12.5), 4.60 (d, 1H, *J* = 12.0 Hz), 4.50 (d, 1H, *J* = 12.5 Hz), 4.47 (d, 1H, *J* = 11.5 Hz), 4.35-4.38 (m, 1H), 4.29-4.30 (m, 1H), 4.27 (s, 1H), 4.17-4.20 (m, 1H). 3.71 (dd, 1H, *J* = 4.0 Hz, *J* = 10.5 Hz), 3.61 (dd, 1H, *J* = 2.5 Hz, *J* = 11.0 Hz).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 157.7, 138.4, 138.2, 138.1, 132.7, 128.3(3), 128.2, 128.1, 128.0, 127.9, 127.6, 127.5, 117.5, 95.7, 95.3, 74.0, 73.3, 71.1, 69.7, 69.7, 68.7, 68.1.
HRMS (ESI-TOF) m/z: [M+NH<sub>4</sub>]<sup>+</sup> calcd for C<sub>30</sub>H<sub>32</sub>O<sub>5</sub>NH<sub>4</sub> 490.2588, found 495.2589



(2*S*,3*S*,5*R*,6*R*)-3-allyl-2,5-bis(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-4*H*-pyran-4one (13a Minor) and (2*S*,3*R*,5*R*,6*R*)-3-allyl-2,5-bis(benzyloxy)-6-

((benzyloxy)methyl)tetrahydro-4*H*-pyran-4-one (13b Major): Compounds 13a and 13b were obtained as a mixture from 12 (200 mg, 0.42 mmol) by following general procedure C. Combined yield: 159.9 mg, 80%, (13a:13b in 2:5 ratio), colourless gel.  $R_f = 0.7$ . (10% EtOAc/hexane). Both the diastereomers were separated by flash column chromatography. Compound 13a: 46 mg, 23%.  $[\alpha]_D^{25} = 122.0$  (*c* 0.50, CHCl<sub>3</sub>).

<sup>1</sup>**H NMR** (**500 MHz**, **CDCl**<sub>3</sub>):  $\delta$  7.30-7.7.36 (m, 15H), 5.68-5.75 (m, 1H, H-8), 5.20 (d, 1H, *J* = 3.5 Hz, H-1), 4.99-5.04 (m, 2H, H-9), 4.91(d, 1H, *J* = 11.0 Hz, ), 4.68 (d, 1H, *J* = 12.0 Hz), 4.65 (d, 1H, *J* = 12.5 Hz), 4,53-4.55 (m, 1H), 4.47 (d, 1H, *J* = 12.0 Hz), 4.41 (d, 1H, *J* = 11.0 Hz), 4.25 (d, 1H, *J* = 10.0 Hz, H-4), 4.07 (d, 1H, *J* = 9.5 Hz, H-5), 3.79-3.82 (m, 1H, H-6a), 3.71-3.73 (m, 1H, H-6b), 2.80-2.84 (m, 1H, H-2), 2.57-2.62 (m, 1H, H-7a), 2.18-2,24 (m, 1H, H-7b).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 204.5, 137.9, 137.5, 136.8, 135.0, 128.4, 128.3(2), 128.2, 128.0, 127.9, 127.8, 127.8, 127.7, 116.9, 100.0, 79.0, 73.6, 73.3, 73.3, 69.3, 68.5, 53.3, 28.1.

HRMS (ESI-TOF) m/z: [M+Na]<sup>+</sup> calcd for C<sub>30</sub>H<sub>32</sub>O<sub>5</sub>Na 495.2147, found 495.2145. Compound 13b: 114 mg, 57%.  $[\alpha]_D^{25} = 87.7$  (*c* 0.30, CHCl<sub>3</sub>).

<sup>1</sup>**H NMR** (**500 MHz**, **CDCl**<sub>3</sub>): δ 7.30-7.34 (m, 15H), 5.68-5.73 (m, 1H, H-8), 5.09-5.19 (m, 1H, H-9), 5.06 (d, 1H, *J* = 18 Hz, H-1), 4.99 (d, 1H, *J* =11.5), 4.85-4.91 (m,1H), 4.66-4.72 (m, 2H), 4.49-4.57 (m, 2H), 4.41 (d, 1H, *J* = 9 Hz), 4,27 (dd, 1H, *J* = 2 Hz, *J* = 10 Hz, H-4), 4.06-4.12 (m, 1H, H-5), 3.75 (dd, 2H, *J* = 10.5 Hz, *J* = 30 Hz, H-6), 2.78-2.88 (m, 1H, H-2), 2.27-2.61 (m, 2H, H-7).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 206.6, 138.1, 137.3, 136.9, 133.8, 128.5, 128.4, 128.2, 128.1, 127.9, 127.8, 127.7, 127.6, 127.6, 117.7, 100.7, 73.6, 73.5, 73.3, 72.9, 69.1, 68.7, 56.0, 34.1.
HRMS (ESI-TOF) *m/z*: [M+Na]<sup>+</sup> calcd for C<sub>30</sub>H<sub>32</sub>O<sub>5</sub>Na 495.2147, found 495.2145.



(2*R*,3*S*,4*R*)-3-(benzyloxy)-2-((benzyloxy)methyl)-4-((3-methylbut-2-en-1-yl)oxy)-3,4dihydro-2*H*-pyran (14): Compound 14 was synthesized from 9<sup>2</sup> (400 mg, 1.22 mmol) by following general procedure **D**. Yield: 444.7 mg, 92%, colorless gel.  $R_f = 0.5$  (10% EtOAc/hexane).  $[\alpha]_D^{25} = 18.5$  (*c* 0.20, CHCl<sub>3</sub>).

<sup>1</sup>**H NMR (500 MHz, CDCl<sub>3</sub>):** δ 7.30-7.37 (m, 10H), 6.44 (d, 1H, *J* = 6.0 Hz), 5.38 (t, 1H, *J* = 5.5 Hz), 4.88-4.90 (m, 2H), 4.58-4.69 (m, 3H), 4.11-4.15 (m, 2H), 4.02-4.10 (m, 2H), 3.78-3.84 (m, 3H), 1.77 (s, 3H), 1.69 (s, 3H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 144.4, 138.3, 138.0, 136.8, 128.3, 128.3, 127.8, 127.7, 127.6, 127.6, 121.1, 100.3, 76.7, 75.4, 74.3, 73.6, 73.4, 68.6, 64.9, 25.7, 18.0.

**HRMS (ESI-TOF)** *m/z*: [M+H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>30</sub>O<sub>4</sub>H 395.2222, found 395.2217



(2*S*,3*S*,4*S*,5*R*,6*R*)-2,5-bis(benzyloxy)-6-((benzyloxy)methyl)-3-iodo-4-((3-methylbut-2-en-1-yl) oxy) tetrahydro-2*H*-pyran (15): Compound 15 was synthesized from 14 (300 mg, 0.76 mmol) by following general procedure A. Yield: 454.1 mg, 95%, colorless gel.  $R_f = 0.6$  (10% EtOAc/hexane).  $[\alpha]_D^{25} = 38.8$  (*c* 0.25, CHCl<sub>3</sub>). <sup>1</sup>**H NMR (500 MHz, CDCl<sub>3</sub>):**  $\delta$  7.25-7.41 (m, 15H), 5.43-5.47 (m, 1H), 5.35 (s, 1H), 4.93 (d, 1H, *J* = 10.5 Hz), 4.75 (d, 1H, *J* = 12.0 Hz), 4.73 (d, 1H, *J* = 12.0 Hz), 4.59 (d, 1H, *J* = 1.5 Hz), 4.57 (d, 1H, *J* = 12.0 Hz), 4.51-4.53 (m, 2H), 4.19 (dd, 1H, J = 7.0 Hz), 3.93-4.00 (m, 2H), 3.89 (t, 1H, *J* = 8.5 Hz), 3.82 (dd, 1H, *J* = 4.5 Hz, *J* = 11.0 Hz), 3.74 (dd, 1H, *J* = 2.0 Hz, *J* = 11.0 Hz), 3.26 (dd, 1H, *J* = 4.5 Hz, *J* = 8.5 Hz), 1.78 (s, 3H), 1.71 (s, 3H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 138.4(2), 137.5, 136.9, 128.4, 128.3, 128.3(2), 128.0, 128.0, 127.9, 127.6, 127.4, 120.6, 100.7, 76.5, 75.8, 75.2, 73.3, 72.4, 69.4, 68.9, 65.3, 34.0, 25.8, 18.1.
HRMS (ESI-TOF) *m/z*: [M+Na]<sup>+</sup> calcd for C<sub>32</sub>H<sub>37</sub> IO<sub>5</sub>Na 651.1583, found 651.1578



(2*R*,3*R*,6*S*)-3,6-bis(benzyloxy)-2-((benzyloxy)methyl)-4-((3-methylbut-2-en-1-yl)oxy)-3,6dihydro-2*H*-pyran (16): Compound 16 was synthesized from 15 (350 mg, 0.55 mmol) by following general procedure **B.** Yield: 270.3 mg, 97%, colorless gel.  $R_f = 0.5$  (10% EtOAc/hexane).

<sup>1</sup>**H NMR** (**500 MHz**, **CDCl**<sub>3</sub>):  $\delta$  7.23-7.34 (m, 15H), 5.39-5.42 (m, 1H), 5.29 (d, 1H, J = 3.5 Hz), 4.85 (d, 1H, J = 11.0 ), 4.78 (d, 1H, J = 3.5 Hz), 4.76 (d, 1H, J = 12.0 Hz), 4.61 (d, 1H, J = 12.0 Hz), 4.57 (d, 1H, J = 11.5 Hz), 4.46 (d, 1H, J = 12.0 Hz), 4.42 (d, 1H, J = 11.0 Hz), 4.29 (dd, 1H, J = 6.5 Hz, J = 11.5 Hz), 4.21-4.24 (m, 2H), 4.14-4.17 (m, 1H), 3.67 (dd, 1H, J = 4.0 Hz, J = 10.5 Hz), 3.58 (dd, 1H, J = 2 Hz, J = 10.5 Hz), 1.76 (s, 3H), 1.67 (s, 3H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 158.0, 138.5, 138.3, 138.2, 137.7, 128.3 (2), 128.2, 128.1, 128.1, 127.9, 127.6, 127.5, 127.5, 119.3, 95.5, 95.2, 73.7, 73.3, 71.1, 69.7, 69.6, 68.7, 64.3, 25.7, 18.2

HRMS (ESI-TOF) *m/z*: [M+NH<sub>4</sub>]<sup>+</sup> calcd for C<sub>32</sub>H<sub>36</sub>O<sub>5</sub>NH<sub>4</sub> 518.2906, found 518.2901



(2S,3S,5R,6R)-2,5-bis(benzyloxy)-6-((benzyloxy)methyl)-3-(2-methylbut-3-en-2-yl)tetrahydro-4H-pyran-4-one(17a) and (2S,3R,5R,6R)-2,5-bis(benzyloxy)-6-((benzyloxy)methyl)-3-(2-methylbut-3-en-2-yl)tetrahydro-4H-pyran-4-one (17b):

Compounds **17a** and **17b** were obtained as inseparable mixture from **16** (200 mg, 0.399 mmol) by following general **procedure C**. Combined yield: 176 mg, 88%, **17a**:**17b** in 1:2 ratio), colorless gel.  $R_f = 0.5$ . (10% EtOAc/hexane).

#### Selected data for Major Product 17b:

<sup>1</sup>**H NMR (500 MHz, CDCl<sub>3</sub>):** δ 7.30-7.35 (m, 15H), 5.93 (dd, 1H, *J* = 11 Hz, *J* = 17.5 Hz) 5.21 (s, 1H), 4.95-4.98 (m, 1H), 4.91 (d, 1H, *J* = 11.0 Hz), 4.86 (d, 1H, *J* = 11.0 Hz), 4.64-4.69 (m, 2H), 4.49-4.53 (m, 3H), 4.23 (d, 1H, *J* = 10.0 Hz), 4.12-4.14 (m, 1H), 4.75-4.78 (m, 1H), 3.72 (dd, 1H, *J* = 2.0 Hz, *J* = 11.0 Hz), 2.63 (s, 1H), 1.10 (s, 3H), 1.09 (s, 3H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 206.3, 145.3, 138.2, 137.3, 137.1, 128.5, 128.4, 128.3 (3), 127.7 (2), 127.6, 127.4, 112.5, 99.0, 78.5, 73.4, 73.2, 72.2, 69.0, 68.8, 65.9, 37.8, 27.7, 24.6.
HRMS (ESI-TOF) *m/z*: [M+NH<sub>4</sub>]<sup>+</sup> calcd for C<sub>32</sub>H<sub>36</sub>O<sub>5</sub>NH<sub>4</sub> 518.2906, found 518.2907.



(2*R*,3*S*,4*R*)-3-(benzyloxy)-2-((benzyloxy)methyl)-4-(cinnamyloxy)-3,4-dihydro-2*H*-pyran (18): Compound 18 was synthesized from 9<sup>2</sup> (400 mg, 1.22 mmol) by following general procedure D. Yield: 488.1 mg, 90%, colorless gel.  $R_f = 0.6$  (10% EtOAc/hexane).  $[\alpha]_D^{25} = 0.8$  (*c* 0.25, CHCl<sub>3</sub>).

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.27-7.39 (m, 15H), 6.63 (d, 1H, J = 15.5 Hz), 6.46 (d, 1H, J = 6.0 Hz), 6.30 (dt, 1H, J = 6.0 Hz, J = 10.0 Hz), 4.88-4.91 (m, 2H), 4.71 (d, 1H, J = 11.5 Hz), 4.64 (d, 1H, J = 12.0 Hz), 4.60 (d, 1H, J = 12.0 Hz), 4.28-4.32 (m, 1H), 4.20-4.24 (m, 2H), 4.08-4.12 (m, 1H), 3.88 (dd, 1H, J = 6.5 Hz, J = 8.5 Hz), 3.80-3.85 (m, 2H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 144.7, 138.2, 137.9, 136.6, 132.2, 128.5, 128.4, 128.3, 127.9, 127.7, 127.7, 127.6, 127.6, 126.4, 126.1, 100.1, 76.7, 75.7, 74.4, 73.8, 73.5, 69.1, 68.5 HRMS (ESI-TOF) m/z: [M+Na]<sup>+</sup> calcd for C<sub>29</sub>H<sub>30</sub>O<sub>4</sub>Na 465.2036, found 465.2035



(2S,3S,4S,5R,6R)-2,5-bis(benzyloxy)-6-((benzyloxy)methyl)-4-(cinnamyloxy)-3iodotetrahydro-2H-pyran (19): Compound 19 was synthesized from 18 (400 mg, 0.90 mmol)

by following general **procedure A.** Yield: 587.1 mg, 96%, colorless gel.  $R_f = 0.7$  (10% EtOAc/hexane).  $[\alpha]_D^{25} = 16.1$  (*c* 0.75, CHCl<sub>3</sub>).

<sup>1</sup>**H NMR** (**500 MHz**, **CDCl**<sub>3</sub>):  $\delta$  7.27-7.44 (m, 20H), 6.69 (d, 1H, *J* = 16.0 Hz), 6.35 (dt, 1H, *J* = 6.0 Hz, *J* = 15.5 Hz), 5.36 (s, 1H), 4.95 (d, 1H, *J* = 11.0 Hz), 4.78(d, 1H, *J* = 12.5 Hz), 4.73 (d, 1H, *J* = 11.5 Hz), 4.56-4.61 (m, 3H), 4.52 (d, 1H, *J* = 12.0 Hz), 4.36 (dd, 1H, *J* = 6.0 Hz, *J* = 12.5 Hz), 3.96 (m, 2H), 3.83-3.86 (m, 1H), 3.75 (d, 1H, *J* = 10.5 Hz), 3.38 (t, 1H, *J* = 4.0 Hz).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 138.3, 138.2, 136.8, 136.5, 132.8, 128.5, 128.4(2), 128.3, 128.3, 128.0, 128.0, 127.9, 127.7, 127.6, 127.5, 126.5, 125.5, 100.7, 76.7, 76.1, 75.2, 73.4, 72.4, 69.8, 69.4, 68.8, 33.9

HRMS (ESI-TOF) *m/z*: [M+Na]<sup>+</sup> calcd for C<sub>36</sub>H<sub>37</sub>IO<sub>5</sub>Na 699.1578, found 699.1578



(2*R*,3*R*,6*S*)-3,6-bis(benzyloxy)-2-((benzyloxy)methyl)-4-(cinnamyloxy)-3,6-dihydro-2*H*pyran (20): Compound 20 was synthesized from 19 (400 mg, 0.59 mmol) by following general procedure B. Yield: 308.1 mg, 95%, colorless gel.  $R_f = 0.6$  (10% EtOAc/hexane).  $[\alpha]_D^{25} = 55.1$ (*c* 0.22, CHCl<sub>3</sub>).

<sup>1</sup>**H** NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  7.27-7.38 (m, 20H), 6.69 (d, 1H, *J* = 16.0 Hz), 6.35 (dt, 1H, *J* = 6.0 Hz, *J* = 16 Hz), 5.33 (d, 1H, *J* = 3.5 Hz), 4.92 (d, 1H, *J* = 11.5 Hz), 4.88 (d, 1H, *J* = 3.5 Hz), 4.80 (d, 1H, *J* = 11.5 Hz), 4.65 (d, 1H, *J* = 12.5 Hz), 4.61 (d, 1H, *J* = 11.5 Hz), 4.49-4.54 (m, 3H), 4.20-4.45 (m, 1H), 4.30 (d, 1H, *J* = 9.5 Hz), 4.19-4.22 (m, 1H), 3.72 (dd, 1H, *J* = 4.0 Hz, *J* = 10.5 Hz), 3.62 (dd, 1H, *J* = 2.0 Hz, *J* = 10.5 Hz).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 157.8, 138.4, 138.3, 138.2, 136.4, 133.0, 128.6, 128.3, 128.2, 128.1, 128.0, 127.9, 127.9, 127.6, 127.6, 127.5, 126.5, 123.9, 95.9, 95.4, 74.0, 73.4, 71.3, 69.8, 68.8, 68.0

**HRMS** (**ESI-TOF**) *m/z*: [M+Na]<sup>+</sup> calcd for C<sub>36</sub>H<sub>36</sub>O<sub>5</sub>Na 571.2455, found 571.2454



#### (2S,3R,5R,6R)-2,5-bis(benzyloxy)-6-((benzyloxy)methyl)-3-((R)-1-

phenylallyl)tetrahydro-4*H*-pyran-4-one (21) : Compound 21 was synthesized from 20 (245.9 mg, 0.54 mmol) by following general procedure C. Yield: 245.9 mg, 82%, colorless gel.  $R_f = 0.6$  (10% EtOAc/hexane).  $[\alpha]_D^{25} = 70.8$  (*c* 0.25, CHCl<sub>3</sub>).

<sup>1</sup>**H NMR (400 MHz, CDCl<sub>3</sub>):**  $\delta$  7.19-7.37 (m, 20H), 5.88-5.97 (m, 1H), 5.06 (d, 1H, *J* = 7.6 Hz), 5.03 (s, 1H), 4.88 (d, 1H, *J* = 11.2 Hz), 4.76 (s, 1H), 4.70 (d, 1H, *J* = 12.0 Hz), 4.60 (d, 1H, *J* = 12.0 Hz), 4.55 (d, 1H, *J* = 12.0 Hz), 4.43 (d, 1H, *J* = 11.2 Hz), 4.33-4.38 (m, 2H), 4.08-4.11 (m, 1H), 3.83 (dd, 1H, *J* = 3.6 Hz, *J* = 10.8 Hz), 3.72-3.77 (m, 2H), 3.11 (d, 1H, *J* = 11.6 Hz).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 205.6, 140.6, 138.3, 138.1, 137.4, 136.9, 129.0, 128.4, 128.4, 128.4, 128.4, 128.3, 128.0, 127.6(2), 127.5(3), 127.2, 116.2, 99.9, 77.4, 73.6, 73.4, 73.1, 69.3, 68.8, 61.9, 50.6

HRMS (ESI-TOF) *m/z*: [M+Na]<sup>+</sup> calcd for C<sub>36</sub>H<sub>36</sub>O<sub>5</sub>Na 571.2455, found 571.2454



(2*R*,3*S*,4*R*)-3-(benzyloxy)-2-((benzyloxy)methyl)-4-(((E)-3,7-dimethylocta-2,6-dien-1yl)oxy)-3,4-dihydro-2*H*-pyran (22): Compound 22 was synthesized from 9<sup>2</sup> (500 mg, 1.53 mmol) by following general procedure D. Yield: 673.24 mg, 95%, colorless gel.  $R_f = 0.6$  (10% EtOAc/hexane).  $[\alpha]_D^{25} = 6.6$  (*c* 0.30, CHCl<sub>3</sub>).

<sup>1</sup>**H NMR (500 MHz, CDCl<sub>3</sub>):** δ 7.32-7.39 (m, 10H), 6.46 (dd, 1H, *J* = 1.0 Hz, *J* = 6.0 Hz), 5.39-5.42 (m, 1H), 5.13-5.16 (m, 1H), 4.89-4.92 (m, 2H), 4.70 (d, 1H, *J* = 11.5 Hz), 4.65 (d, 1H, *J* = 12.5 Hz), 4.60 (d, 1H, *J* = 12.0 Hz), 4.16-4.20 (m, 2H), 4.07-4.12 (m, 2H), 3.82-3.87 (m, 3H), 2.12-2.18 (m, 2H), 2.07-2.10 (m, 2H), 1.73 (d, 3H, *J* = 1.0 Hz), 1.70 (s, 3H), 1.65 (s, 3H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 144.5, 140.1, 138.4, 138.1, 131.7, 128.4, 128.4, 127.9, 127.8, 127.7, 127.7, 124.0, 121.0, 100.5, 76.8, 75.6, 74.4, 73.7, 73.5, 68.7, 65.1, 39.6, 26.4, 25.8, 17.8, 16.6

**HRMS (ESI-TOF)** *m/z*: [M+H]<sup>+</sup> calcd for C<sub>30</sub>H<sub>38</sub>O<sub>5</sub>H 463.2843, found 463.2844.



(2*S*,3*S*,4*S*,5*R*,6*R*)-2,5-bis(benzyloxy)-6-((benzyloxy)methyl)-4-(((E)-3,7-dimethylocta-2,6dien-1-yl) oxy)-3-iodotetrahydro-2*H*-pyran (23): Compound 23 was synthesized from 22 (500 mg, 1.08 mmol) by following general procedure A. Yield: 677.7 mg, 90%, colorless gel.  $R_f = 0.6$  (10% EtOAc/hexane).  $[\alpha]_D^{25} = 73.2$  (*c* 0.25, CHCl<sub>3</sub>).

<sup>1</sup>**H NMR** (**500 MHz, CDCl<sub>3</sub>**):  $\delta$  7.21-7.41 (m, 15H), 5.44 (t, 1H, *J* = 6.5 Hz), 5.34 (s, 1H), 5.11 (t, 1H, *J* = 6.5 Hz), 4.92 (d, 1H, *J* = 10.5 Hz), 4.74 (d, 1H, *J* = 12.5 Hz), 4.71 (d, 1H, *J* = 12.5 Hz), 4.56-4.58 (m, 2H), 4.49-4.52 (m, 2H), 4.20 (dd, 1H, *J* = 7.0 Hz), 4.00 (dd, 1H, *J* = 6.5 Hz, *J* = 11.0 Hz), 3.92-3.95 (m, 1H), 3.86-3.91 (m, 1H), 3.81 (dd, 1H, *J* = 4.5 Hz, *J* = 10.5 Hz), 3.71-3.73 (m, 1H), 3.25 (dd, 1H, *J* = 4.0 Hz, *J* = 8.5 Hz), 2.09-2.12 (m, 2H), 2.04-2.07 (m, 2H), 1.69 (s, 6H), 1.61 (s, 3H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 140.8, 138.5, 137.0, 131.7, 128.5, 128.3, 128.3(2), 128.1, 128.0 (2), 127.6(2), 127.5, 123.9, 120.4, 100.8, 76.6, 75.9, 75.2, 73.4, 72.5, 69.5, 69.0, 65.5, 39.6, 34.2, 26.4, 25.7, 17.7, 16.6

**HRMS** (**ESI-TOF**) *m/z*: [M+NH<sub>4</sub>]<sup>+</sup> calcd for C<sub>37</sub>H<sub>45</sub>IO<sub>5</sub>H 714.2655, found 714.2650.



(2R,3R,6S)-3,6-bis(benzyloxy)-2-((benzyloxy)methyl)-4-(((E)-3,7-dimethylocta-2,6-dien-1-yl)oxy)-3,6-dihydro-2*H*-pyran (24): Compound 24 was synthesized from 23 (500 mg, 0.71 mmol) by following general procedure B. Yield: 399.9 mg, 98%, colorless gel.  $R_f = 0.6$  (10% EtOAc/hexane).  $[\alpha]_D^{25} = 84.0$  (c 0.17, CHCl<sub>3</sub>).

<sup>1</sup>**H NMR (500 MHz, CDCl<sub>3</sub>):** δ 7.23-7.35 (m, 15H), 5.41 (t, 1H, *J* = 6.5 Hz), 5.29 (d, 1H, *J* = 4.0 Hz), 5.07-5.10 (m, 1H), 4.85 (d, 1H, *J* = 10.5 Hz), 4.78 (d, 1H, *J* = 3.5 Hz), 4.76 (d, 1H, *J* = 11.5 Hz), 4.61 (d, 1H, *J* = 12.5 Hz), 4.57 (d, 1H, *J* = 12.0 Hz), 4.46 (d, 1H, *J* = 12.5 Hz),

4.43 (d, 1H, *J* = 11.0 Hz), 4.31 (dd, 1H, *J* = 6.5 Hz, *J* = 11.5 Hz), 4.24-4.26 (m, 1H), 4.22 (d, 1H, *J* = 9.5 Hz), 4.14-4.17 (m, 1H), 3.67 (dd, 1H, *J* = 4.0 Hz, *J* = 10.5 Hz), 3.58 (dd, 1H, J = 2.0 Hz, J = 10.5 Hz), 2.08-2.11 (m, 2H), 2.03-2.06 (m, 2H), 1.66 (s, 6H), 1.59 (s, 3H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 158.0, 141.0, 138.5, 138.3, 138.2, 131.8, 128.4, 128.2 (2), 128.1, 127.9, 127.6 (3), 123.8, 119.1, 95.5, 95.3, 73.8, 73.4, 71.1, 69.8, 69.7, 68.8, 64.3, 39.5, 26.4, 25.7, 17.7, 16.6

**HRMS** (**ESI-TOF**) *m/z*: [M+Na] calcd for C<sub>37</sub>H<sub>44</sub>O<sub>5</sub>Na 591.3086, found 591.3084.



(2*S*,3*R*,5*R*,6*R*)-2,5-bis(benzyloxy)-6-((benzyloxy)methyl)-3-(3,7-dimethylocta-1,6-dien-3-yl)tetrahydro-4*H*-pyran-4-one (25): Compound 25 was synthesized as an inseparable diastereomeric mixture from 24 (250 mg, 0.43 mmol) by following general procedure C. Yield: 217.4 mg, 87%, colorless gel.  $R_f$  = 0.5. (10% EtOAc/hexane).

Selected data for major diastereomer of 25:

<sup>1</sup>**H** NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.29-7.36 (m, 15H), 5.88 (dd, 1H, *J* = 10.8 Hz, *J* = 17.6 Hz), 5.21 (s, 1H), 5.04-5.07 (m, 2H), 4.89 (d, 1H, *J* = 17.2 Hz), 4.88-4.93 (m, 2H), 4.84 (d, 1H, *J* = 11.2 Hz), 4.69 (d, 1H, *J* = 12.0 Hz), 4.65 (d, 1H, *J* = 12.0 Hz), 4.52 (d, 1H, *J* = 2.8 Hz), 4.50 (d, 1H, *J* = 3.2 Hz), 4.44 (d, 1H, *J* = 11.2 Hz), 4.18 (d, 1H, *J* = 10.0 Hz), 4.07-4.12 (m, 1H), 3.77 (dd, 1H, *J* = 4.0 Hz, *J* = 10.4 Hz), 3.72 (dd, 1H, *J* = 2.0 Hz, *J* = 10.8 Hz), 2.75 (s, 1H), 1.93-2.03 (m, 1H), 1.82-1.90 (m, 1H), 1.70 (s, 3H), 1.60 (s, 3H), 1.14 (s, 3H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 206.1, 143.6, 138.2, 137.3, 137.1, 131.8, 128.5, 128.4, 128.3, 128.0, 127.8, 127.7, 127.6, 127.5, 127.4, 124.0, 113.4, 98.2, 78.7, 73.3, 73.2, 72.3, 69.0, 68.9, 65.2, 40.7, 39.6, 25.7, 22.5, 21.6, 17.7.

**HRMS** (**ESI-TOF**) *m/z*: [M+H] calcd for C<sub>37</sub>H<sub>44</sub>O<sub>5</sub>H 569.3262, found 569.3267.



(2*R*,3*S*,4*R*)-3-(benzyloxy)-2-((benzyloxy)methyl)-4-(prop-2-yn-1-yloxy)-3,4-dihydro-2*H*pyran (26): Compound 26 was synthesized from 9<sup>2</sup> (400 mg, 1.22 mmol) by following general procedure **D.** Yield: 410.8 mg, 92%, colourless gel.  $R_f = 0.5$  (10% EtOAc/hexane).  $[\alpha]_D^{25} =$ 55.8 (*c* 0.50, CHCl<sub>3</sub>).

<sup>1</sup>**H NMR (500 MHz, CDCl<sub>3</sub>):** δ 7.31-7.38 (m, 10H), 6.46 (dd, 1H, *J* = 1.5 Hz, *J* = 7.5 Hz), 4.90 (dd, 1H, *J* = 3.5 Hz, *J* = 8.0 Hz), 4.89 (d, 1H, *J* = 13.0 Hz), 4.68 (d, 1H, *J* = 14.0 Hz), 4.62 (s, 1H), 4.61 (s, 1H), 4.33-4.36 (m, 1H), 4.25-4.26 (m, 2H), 4.08-4.13 (m, 1H), 3.80-3.87 (m, 3H), 2.46 (t, 1H, *J* = 5.0 Hz).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 145.1, 138.2, 138.0, 128.4(2), 128.0, 127.8 (2), 127.7, 99.4, 80.0, 76.8, 75.4, 74.5, 74.2, 73.7, 73.5, 68.5, 55.9

HRMS (ESI-TOF) *m/z*: [M+NH4]<sup>+</sup> calcd for C<sub>23</sub>H<sub>24</sub>O<sub>4</sub>NH4 382.2013, found 382.2013



(2*S*,3*S*,4*S*,5*R*,6*R*)-2,5-bis(benzyloxy)-6-((benzyloxy)methyl)-3-iodo-4-(prop-2-yn-1-yloxy)tetrahydro-2*H*-pyran (27): Compound 27 was synthesized from 26 (300 mg, 0.82 mmol) by following general procedure A. Yield: 394.19 mg, 80%, colorless gel.  $R_f = 0.6$  (10% EtOAc/hexane).  $[\alpha]_D^{25} = 30.5$  (*c* 0.35, CHCl<sub>3</sub>).

<sup>1</sup>**H NMR** (**500 MHz**, **CDCl**<sub>3</sub>):  $\delta$  7.26-7.44 (m, 15H), 5.34 (s, 1H), 4.90 (d, 1H, J = 10.5 Hz), 4.78 (d, 1H, J = 12.0 Hz), 4.73 (d, 1H, J = 12.0 Hz), 4.60 (dd, 1H, J = 1. Hz, J = 4.5 Hz), 4.58 (d, 1H, J = 12.0 Hz), 4.53 (t, 2H, J = 10.0 Hz), 4.38 (dd, 1H, J = 2.0 Hz, J = 15.0 Hz), 4.28 (dd, 1H, J = 2.5, J = 16.0 Hz), 3.95 (d, 2H, J = 5.5 Hz), 3.81-3.84 (m, 1H), 3.73 (d, 1H, J = 10.5 Hz), 3.50-3.52 (m, 1H), 2.49 (t, 1H, J = 2.0 Hz).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 138.4, 138.2, 136.9, 128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 127.8, 127.7, 127.5, 100.7, 79.3, 76.7, 76.0, 75.3, 75.1, 73.4, 72.4, 69.5, 68.8, 56.8, 33.1.
HRMS (ESI-TOF) *m/z*: [M+Na]<sup>+</sup> calcd for C<sub>30</sub>H<sub>31</sub>IO<sub>5</sub>Na 621.1108, found 621.1107



(2*R*,3*R*,6*S*)-3,6-bis(benzyloxy)-2-((benzyloxy)methyl)-4-(prop-2-yn-1-yloxy)-3,6-dihydro-2H-pyran (28): Compound 28 was synthesized from 27 (300 mg, 0.50 mmol) by following general procedure **B**. Yield: 212.2 mg, 90%, colorless gel.  $R_f = 0.5$  (10% EtOAc/hexane).  $[\alpha]_D^{25}$ = 24.2 (*c* 0.70, CHCl<sub>3</sub>).

<sup>1</sup>**H NMR** (**500 MHz**, **CDCl**<sub>3</sub>):  $\delta$  7.28-7.37 (m, 15H), 5.33 (d, 1H, *J* = 3.5 Hz), 4.88-4.93 (m, 2H), 4.79 (d, 1H, *J* = 12.0 Hz), 4.64 (d, 1H, *J* = 12.0 Hz), 4.60 (d, 1H, J = 12.0 Hz), 4.54 (dd, 1H, *J* = 2.5 Hz, *J* = 10.5), 4.45-4.51 (m, 3H), 4.28 (d, 1H, *J* = 9.0 Hz), 4.16-4.21 (m, 1H), 3.70 (dd, 1H, *J* = 4.0 Hz, *J* = 10.5 Hz), 3.61 (dd, 1H, *J* = 2.0 Hz, *J* = 10.5 Hz), 2.54 (t, 1H, *J* = 2.5 Hz).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 156.9, 138.3, 138.1(2), 128.4(3), 128.3, 128.2, 128.1, 127.9, 127.7, 127.6, 96.7, 95.1, 77.9, 75.7, 74.1, 73.4, 71.0, 69.9, 69.7, 68.6, 55.2

**HRMS** (**ESI-TOF**) *m/z*: [M+Na]<sup>+</sup> calcd for C<sub>30</sub>H<sub>30</sub>O<sub>5</sub>Na 493.1985, found 493.1986.



#### (2S,5R,6R,Z)-3-allylidene-2,5-bis(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-4H-

**pyran-4-one (29):** Compound **29** was synthesized from **28** (200 mg, 0.42 mmol) by following general **procedure C.** Yield: 133.9 mg, 67%, colorless gel.  $R_f = 0.5$ . (10% EtOAc/hexane).  $[\alpha]_D^{25} = 32.0$  (*c* 0.05, CHCl<sub>3</sub>).

<sup>1</sup>**H NMR (500 MHz, CDCl<sub>3</sub>):**  $\delta$  7.31-7.36 (m, 15H), 7.17 (d, 1H, *J* = 15.0 Hz), 6.30-6.39 (m, 1H), 5.77 (m, 2H), 5.65 (d, 1H, *J* = 12.5 Hz), 5.10 (d, 1H, *J* = 13.5 Hz), 4.81 (d, 1H, *J* = 15.0 Hz), 4.67 (d, 1H, *J* = 15.0 Hz), 4.53-4.63 (m, 3H), 4.35-4.39 (m, 1H), 4.12 (d, 1H, *J* = 13.0 Hz), 3.76 (dd, 1H, *J* = 5.0 Hz, *J* = 13.0 Hz), 3.68 (dd, 1H, *J* = 2.5 Hz, *J* = 13.5 Hz).

<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 197.1, 139.4(2), 137.9, 137.7, 137.0, 132.1, 130.6, 129.7, 128.4, 128.4, 128.4, 128.3, 128.3, 128.0, 127.8, 127.7, 95.2, 77.2, 74.7, 73.5, 69.3, 69.1, 68.7
HRMS (ESI-TOF) *m/z*: [M+Na]<sup>+</sup> calcd for C<sub>30</sub>H<sub>30</sub>O<sub>5</sub>Na 493.1985, found 493.1985



(2*S*,3*S*,4*S*)-4-(allyloxy)-3-(benzyloxy)-2-methyl-3,4-dihydro-2*H*-pyran (30): Compound 30 was synthesized from S1 (500 mg, 2.27 mmol) by following general procedure D. Yield: 460.9 mg, 78%, colorless gel.  $R_f = 0.7$  (10% EtOAc/hexane).  $[\alpha]_D^{25} = 6.1$  (*c* 0.75, CHCl<sub>3</sub>).

<sup>1</sup>**H NMR (500 MHz, CDCl<sub>3</sub>):** δ 7.29-7.37 (m, 5H), 6.34 (dd, 1H, *J* = 1.0 Hz, *J* = 6.0 Hz), 5.90-5.98 (m, 1H), 5.28-5.33 (m, 1H), 5.17-5.19 (m, 1H), 4.88 (d, 1H, *J* = 11.5 Hz), 4.82 (dd, 1H, *J* = 2.5 Hz, *J* = 6.0 Hz), 4.70 (d, 1H, *J* = 11.5 Hz), 4.12-4.15 (m, 2H), 4.02-4.06 (m, 1H), 3.91-3.96 (m, 1H), 3.42 (dd, 1H, *J* = 6.5 Hz), 1.37 (d, 3H, *J* = 6.0 Hz).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 144.7, 138.3, 135.0, 128.4, 128.0, 127.8, 116.8, 100.3, 79.5, 76.5, 74.1, 74.0, 69.5, 17.5

**HRMS (ESI-TOF)** *m/z*: [M+H] calc for C<sub>16</sub>H<sub>20</sub>O<sub>3</sub>H 261.1491, found 261.1493.



(2*R*,3*R*,4*R*,5*S*,6*S*)-4-(allyloxy)-2,5-bis(benzyloxy)-3-iodo-6-methyltetrahydro-2*H*-pyran (31): Compound 31 was synthesized from 30 (400 mg, 1.15 mmol) by following general procedure A. Yield: 607.7 mg, 80%, colorless gel.  $R_f = 0.5$  (10% EtOAc/hexane).  $[\alpha]_D^{25} = -28.8$  (*c* 2.00, CHCl<sub>3</sub>).

<sup>1</sup>**H** NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  7.33-7.39 (m, 10H), 5.97-6.04 (m, 1H), 5.39 (dd, 1H, J = 1.5 Hz, J = 17.5 Hz), 5.24 (d, 2H, J = 10 Hz ), 4.98 (d, 1H, J = 10.5 Hz), 4.69 (d, 1H, J = 12.0 Hz), 4.67 (d, 1H, J = 11 Hz), 4.56 (d, 1H, J = 4.0 Hz), 4.50 (d, 1H, J = 12 Hz), 4.19 (dd, 1H, J = 5.5 Hz, J = 12.5 Hz), 4.05 (dd, 1H, J = 5.5 Hz, J = 12.5 Hz), 3.87-3.93 (m, 1H), 3.51 (t, 1H, J = 9.0 Hz), 3.23 (dd, 1H, J = 4 Hz, J = 8.5 Hz), 1.36 (d, 3H, J = 6.0 Hz).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 138.3, 136.9, 134.3, 128.4, 128.3, 128.1, 127.9, 127.9, 127.7, 117.2, 100.7, 81.6, 76.6, 75.4, 69.9, 69.4, 68.4, 34.4, 17.9.

HRMS (ESI-TOF) *m/z*: [M+Na] calcd for C<sub>23</sub>H<sub>27</sub>IO<sub>4</sub>Na 517.0852, found 517.0856.



#### (2*S*,3*S*,6*R*)-4-(allyloxy)-3,6-bis(benzyloxy)-2-methyl-3,6-dihydro-2*H*-pyran (32):

Compound **32** was synthesized from **31** (300 mg, 0.60 mmol) by following general **procedure B.** Yield: 173.4 mg, 78%, colorless gel.  $R_f = 0.4$  (10% EtOAc/hexane).  $[\alpha]_D^{25} = -100.6$  (*c* 0.50, CHCl<sub>3</sub>).

<sup>1</sup>**H** NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  7.32-7.36 (m, 10H), 5.96-6.03 (m, 1H), 5.36 (dd, 1H, J = 1.5 Hz, J = 17.5), 5.25 (dd, 1H, J = 1.0 Hz, J = 10.5 Hz), 5.20 (d, 1H, J = 3.5 Hz), 4.93 (d, 1H, J = 11.0 Hz), 4.78 (d, 1H, J = 3.0 Hz), 4.74 (d, 1H, J = 12.0 Hz), 4.59 (d, 1H, J = 11.0 Hz), 4.57 (d, 1H, J = 12.0 Hz), 4.32-4.35 (m, 1H), 4.24-4.28 (m, 1H), 4.12-4.16 (m, 1H), 3.77 (d, 1H, J = 9.0 Hz), 1.24 (d, 3H, J = 6.5 Hz).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 157.7, 138.4, 138.3, 132.7, 128.5, 128.3, 128.2, 128.1, 127.9, 127.6, 127.5, 117.5, 95.8, 95.2, 73.8, 69.6, 68.1, 66.1, 18.2

HRMS (ESI-TOF) *m/z*: [M+NH<sub>4</sub>] calcd for C<sub>23</sub>H<sub>26</sub>O<sub>4</sub>NH<sub>4</sub> 384.2174, found 384.2175.



(2R,3R,5S,6S)-3-allyl-2,5-bis(benzyloxy)-6-methyltetrahydro-4H-pyran-4-one (33a) and (2R,3S,5S,6S)-3-allyl-2,5-bis(benzyloxy)-6-methyltetrahydro-4H-pyran-4-one (33b): Compounds 33a and 33b were was synthesized from 32 (200 mg, 0.42 mmol) by following general procedure C. Yield: 159.9 mg, 58%, 33a:33b (1:2). colorless gel.  $R_f = 0.7$ . (10% EtOAc/hexane).  $[\alpha]_D^{25} = -37.0$  ( $c \ 0.10$ , CHCl<sub>3</sub>).

#### Selected data for the mixture 33a and 33b:

<sup>1</sup>**H** NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  7.31-7.39 (m, 15H), 5.67-5.76 (m, 1.5H), 5.05-5.11 (m, 3H), 4.96-5.01 (m, 1.5H), 4.91-4.94 (m, 2H), 4.69 (dd, 1.5H, *J* = 3.5, 12 Hz), 4.45-4.52 (m, 3H), 4.07-4.14 (m, 1.5H), 3.74 (d, 1H, *J* = 10 Hz), 3.69 (d, 0.5H, *J* = 10 Hz), 2.75-2.81 (m, 1.5H), 2.57-2.62 (m, 0.5H), 2.37-2.49 (m, 2H), 2.19-2.25 (m, 0.5H), 1.40 (d, 1.5H, *J* = 6 Hz), 1.38 (d, 3H, *J* = 6 Hz).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 206.2, 204.0, 137.3, 136.9, 136.8, 135.1, 133.8, 128.3, 128.3, 128.3, 128.2, 127.9, 127.8, 127.7, 117.7, 116.9, 100.5, 99.6, 84.5, 82.0, 73.1, 73.0, 70.1, 69.4, 69.1, 69.0, 56.0, 53.5, 34.3, 28.1, 18.9, 18.8.

**HRMS (ESI-TOF)** *m/z*: [M+NH<sub>4</sub>] calcd for C<sub>23</sub>H<sub>26</sub>O<sub>4</sub>NH<sub>4</sub> 384.2174, found 384.2172.



(2S,3S,4S)-3-(benzyloxy)-4-(((E)-3,7-dimethylocta-2,6-dien-1-yl)oxy)-2-methyl-3,4dihydro-2*H*-pyran (34): Compound 34 was synthesised from S1 500 mg, 2.27 mmol) by following general procedure D. Yield: 728.32 mg, 90%, colorless gel.  $R_f = 0.6$  (10% EtOAc/hexane).

<sup>1</sup>**H NMR** (**500 MHz, CDCl<sub>3</sub>**):  $\delta$  7.29-7.40 (m, 5H), 6.36-6.37 (m, 1H), 5.38-5.41 (m, 1H), 5.10-5.13 (m, 1H), 4.93 (d, 1H, *J* = 11.35 Hz), 4.85-4.87 (m, 1H), 4.73 (d, 1H, *J* = 11.35 Hz), 4.12-4.19 (m, 2H), 4.06-4.09 (m, 1H), 3.92-3.98 (m, 1H), 3.42-3.45 (m, 1H), 2.11-2.14 (m, 2H), 2.04-2.08 (m, 2H), 1.70 (s, 6H), 1.62 (s, 3H), 1.39 (d, 3H, J = 6.4 Hz).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 144.5, 140.0, 138.4, 131.6, 128.3, 127.9, 127.6, 123.9, 121.0, 100.6, 79.5, 76.2, 73.9(2), 65.0, 39.6, 26.3, 25.6, 17.7, 17.5, 16.5

HRMS (ESI-TOF) *m/z*: [M+Na] calcd for C<sub>23</sub>H<sub>32</sub>O<sub>3</sub>Na 379.2249, found 379.2252



(2*R*,3*R*,4*R*,5*S*,6*S*)-2,5-bis(benzyloxy)-4-(((E)-3,7-dimethylocta-2,6-dien-1-yl)oxy)-3-iodo-6-methyltetrahydro-2*H*-pyran (35): Compound 35 was synthesized from 34 (400 mg, 1.12 mmol) by following general procedure A. Yield: 627.7 mg, 95%, colorless gel.  $R_f = 0.7$  (10% EtOAc/hexane).

<sup>1</sup>**H NMR** (**500 MHz**, **CDCl**<sub>3</sub>): δ 7.30-7.36 (m, 10H), 5.42-5.45 (m, 1H), 5.22 (s, 1H), 5.09-5.11 (m, 1H), 4.97 (d, 1H, *J* = 11.0 Hz), 4.66-4.69 (m, 1H), 4.63 (d, 1H, *J* = 11.0 Hz), 4.56 (dd, 1H, *J* = 1.5 Hz, *J* = 4.0 Hz), 4.47 (d, 1H, *J* = 12.0 Hz), 4.19 (dd, 1H, *J* = 7.0 Hz, *J* = 11.5 Hz), 3.99 (dd, 1H, *J* = 6.5 Hz, *J* = 11.0 Hz), 3.84-3.88 (m, 1H), 3.45 (t, 1H, *J* = 9.0 Hz), 3.18 (dd, 1H, *J* = 4.0 Hz, *J* = 8.5 Hz), 2.08-2.13 (m, 2H), 2.03-2.06 (m, 2H), 1.68 (s, 6H), 1.60 (s, 3H), 1.33 (d, 3H, *J* = 6.5 Hz).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 140.6, 138.5, 137.0, 131.6, 128.4, 128.3, 128.0, 127.9, 127.9, 127.6, 123.9, 120.4, 100.7, 81.6, 76.4, 75.4, 69.4, 68.5, 65.4, 39.6, 35.0, 26.3, 25.6, 18.0, 17.7, 16.6

**HRMS (ESI-TOF)** *m/z*: [M+Na] calcd for C<sub>30</sub>H<sub>39</sub>IO<sub>4</sub>Na 613.1791, found 613.1790.



(2*S*,3*S*,6*R*)-3,6-bis(benzyloxy)-4-(((E)-3,7-dimethylocta-2,6-dien-1-yl)oxy)-2-methyl-3,6dihydro-2*H*-pyran(36): Compound 36 was synthesized from 35 450 mg, 0.76 mmol) by following general procedure B. Yield: 328.1 mg, 96%, colorless gel.  $R_f = 0.6$ (10%EtOAc/hexane).  $[\alpha]_D^{25} = -10.0$  (*c* 0.05, CHCl<sub>3</sub>).

<sup>1</sup>**H NMR (500 MHz, CDCl<sub>3</sub>):**  $\delta$  7.28-7.36 (m, 10H), 5.41-5.44 (m, 1H), 5.20 (d, 1H, J = 3.5 Hz), 5.08-5.11 (m, 1H), 4.88 (d, 1H, J = 11.0 Hz), 4.78 (d, 1H, J = 3.0 Hz), 4.74 (d, 1H, J = 12.0 Hz), 4.58 (d, 1H, J = 11.0 Hz), 4.57 (d, 1H, J = 11.5 Hz), 4.32 (dd, 1H, J = 6.5 Hz, J = 11.5 Hz), 4.25 (dd, 1H, J = 6.5, J = 11.5 Hz), 4.10-4.16 (m, 1H), 3.75 (d, 1H, J = 9.0 Hz), 2.09-2.12 (m, 2H), 2.04-2.07 (m, 2H), 1.67 (s, 6H), 1.60 (s, 3H), 1.24 (d, 3H, J = 6.0 Hz).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 157.9, 140.9, 138.5, 138.4, 131.8, 128.3(2), 128.2(2), 128.0, 127.6, 127.5, 123.8, 119.1, 95.3(2), 73.5, 69.6, 66.1, 64.3, 39.5, 26.3, 25.7, 18.2, 17.7, 16.6

**HRMS** (**ESI-TOF**) *m/z*: [M+Na] calcd for C<sub>30</sub>H<sub>38</sub>O<sub>4</sub>Na 485.2668, found 485.2666.



(2*R*,3*S*,5*S*,6*S*)-2,5-bis(benzyloxy)-3-(3,7-dimethylocta-1,6-dien-3-yl)-6-methyltetrahydro-4H-pyran-4-one (37): Compound 37 was synthesized from 36 (300 mg, 0.64 mmol) by following general procedure C. Obtained as an inseparable mixture in 1:1 ratio at the newly

generated quaternary stereo-centre. Yield: 269.9 mg, 90%, colorless gel.  $R_f = 0.6$  (10% EtOAc/hexane).  $[\alpha]_D^{25} = -112.0$  (*c* 0.05, CHCl<sub>3</sub>).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) (Inseparable mixture): δ 205.7 (2), 143.7(2), 137.8, 137.4, 137.2, 136.7, 128.5, 128.4, 128.3, 128.2, 128.1, 127.9 (2), 127.8 (2), 127.6 (2), 124.0 (2), 120.4, 113 (2), 101.6, 98.5, 85.3, 84.9, 83.9, 75.2, 72.9, 71.4, 71.2, 70.1, 68.8, 68.7, 65.1, 40.5, 39.6, 39.4, 33.3, 26.3, 25.6 (2), 22.4, 21.8, 18.8, 17.7, 17.6, 16.7.

HRMS (ESI-TOF) *m/z*: [M+NH<sub>4</sub>] calcd for C<sub>30</sub>H<sub>38</sub>O<sub>4</sub>NH<sub>4</sub> 480.3114, found 480.3120.



#### (2S,3S,4S)-3-(benzyloxy)-4-(cinnamyloxy)-2-methyl-3,4-dihydro-2H-pyran(38):

Compound **38** was synthesized from **S1** (500 mg, 2.27 mmol) by following general **procedure D.** Yield: 702.5 mg, 92%, colorless gel.  $R_f = 0.7$  (10% EtOAc/hexane).

<sup>1</sup>**H NMR (500 MHz, CDCl<sub>3</sub>):**  $\delta$  7.30-7.39 (m, 10H), 6.62 (d, 1H, *J* = 16.0 Hz), 6.37 (dd, 1H, *J* = 1.0 Hz, *J* = 6.0 Hz), 6.30 (dt, 1H, J = 6.0 Hz, J = 16.0 Hz), 4.92 (d, 1H, *J* = 11.0 Hz), 4.87 (dd, 1H, *J* = 2.5 Hz, *J* = 6.0 Hz), 4.75 (d, 1H, *J* = 11.0 Hz), 4.29-4.33 (m, 1H), 4.19-4.29 (m, 2H), 3.93-3.99 (m, 1H), 3.47 (dd, 1H, *J* = 6.5 Hz, *J* = 9.0 Hz), 1.40 (d, 3H, *J* = 6.5 Hz).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 144.8, 138.3, 136.7, 132.2, 128.5, 128.4, 127.9, 127.7, 127.6, 126.4, 126.2, 100.3, 79.6, 76.4, 74.1, 74.0, 69.2, 17.5

HRMS (ESI-TOF) m/z: [M+Na] calcd for C<sub>22</sub>H<sub>24</sub>O<sub>3</sub>Na 359.1623, found 359.1622





**pyran (39):** Compound **39** was synthesized from **38** (400 mg, 1.18 mmol) by following general **procedure A.** Yield: 644.4 mg, 95%, colorless gel.  $R_f = 0.7$  (10% EtOAc/hexane).

<sup>1</sup>**H NMR (500 MHz, CDCl<sub>3</sub>):** δ 7.27-7.38 (m, 15H), 6.67 (d, 1H, *J* = 16.0 Hz), 6.32 (dt, 1H, J = 6.0 Hz, J = 15.5 Hz), 5.23 (s, 1H), 4.99 (d, 1H, *J* = 11.0 Hz), 4.68 (bs, 1H), 4.66 (d, 1H, *J* = 2.5 Hz), 4.57 (dd, 1H, *J* = 1.5 Hz, *J* = 4.0 Hz), 4.47 (d, 1H, *J* = 11.5 Hz), 4.31-4.35 (m, 1H),

4.18-4.22 (m, 1H), 3.86-3.92 (m, 1H), 3.51 (t, 1H, *J* = 9.0 Hz), 3.27 (dd, 1H, *J* = 4.0 Hz, *J* = 8.5 Hz), 1.35 (d, 3H, *J* = 6.5 Hz).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 138.4, 137.0, 136.6, 132.7, 128.5, 128.4, 128.4, 128.0, 127.9, 127.9, 127.7, 126.5, 125.6, 100.7, 81.7, 76.6, 75.5, 69.7, 69.4, 68.6, 34.7, 18.0
HRMS (ESI-TOF) *m/z*: [M+Na] calcd for C<sub>29</sub>H<sub>31</sub>IO<sub>4</sub>Na 593.1165, found 593.1161.



#### (2S,3S,6R)-3,6-bis(benzyloxy)-4-(cinnamyloxy)-2-methyl-3,6-dihydro-2H-pyran (40):

Compound **40** was synthesized from **39** (400 mg, 0.70 mmol) by following general procedure **B**. Yield: 288.5 mg, 93%, colorless gel.  $R_f = 0.6$  (10% EtOAc/hexane).  $[\alpha]_D^{25} = -32.0$  (*c* 0.05, CHCl<sub>3</sub>).

<sup>1</sup>**H NMR (500 MHz, CDCl<sub>3</sub>):** δ 7.26-7.38 (m, 15H), 6.68 (d, 1H, *J* = 16.0 Hz), 6.34 (dt, 1H, J = 5.5 Hz, J = 16.0 Hz), 5.22 (d, 1H, *J* = 3.5 Hz), 4.94 (d, 1H, *J* = 11.5 Hz), 4.85 (d, 1H, *J* = 3.5 Hz), 4.76 (d, 1H, *J* = 12.0 Hz), 4.63 (d, 1H, *J* = 11.0 Hz), 4.58 (d, 1H, *J* = 12.0 Hz), 4.48-4.52 (m, 1H), 4.39-4.43 (m, 1H), 4.14-4.19 (m, 1H), 3.80 (d, 1H, *J* = 9.0 Hz), 1.26 (d, 3H, *J* = 6.5 Hz).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 157.7, 138.4, 138.3, 136.4, 133.0, 128.6, 128.3, 128.3, 128.1, 127.9 (2), 127.6, 127.5, 126.5, 123.9, 95.9, 95.2, 77.1, 73.7, 69.6, 67.9, 66.1, 18.2
HRMS (ESI-TOF) *m/z*: [M+Na]<sup>+</sup> calcd for C<sub>29</sub>H<sub>30</sub>O<sub>5</sub>Na 469.1997, found 469.1985.



(2*R*,3S,5S,6S)-2,5-bis(benzyloxy)-6-methyl-3-(1-phenylallyl)tetrahydro-4*H*-pyran-4-one (41): Compound 41 was synthesized (an inseparable mixture of diastereomers at the allylic position) from 40 (200 mg, 0.45 mmol) by following general procedure C. Combined yield: 175.9 mg, 88%, colorless gel.  $R_f = 0.6$  (10% EtOAc/hexane).  $[\alpha]_D^{25} = -96.6$  (*c* 0.55, CHCl<sub>3</sub>). Data for the major diastereomer of 41: <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.13-7.36 (m, 15H), 5.86-5.94 (m, 1H), 5.04 (s, 1H), 5.01 (d, 1H, J = 5.0 Hz), 4.90 (d, 1H, J = 11.5 Hz), 4.63 (s, 1H), 4.53 (d, 1H, J = 12.0 Hz), 4.43 (d, 1H, J = 12.0 Hz), 4.28 (d, 1H, J = 12.0 Hz), 4.03-4.09 (m, 1H), 3.77 (d, 1H, J = 9.5 Hz), 3.61 (dd, 1H, J = 10.0 Hz, J = 12.0 Hz), 3.06 (d, 1H, J = 12.0 Hz), 1.37 (d, 3H, J = 6.5 Hz). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 205.2, 140.6, 138.1, 137.4, 136.9, 129.0, 128.4, 128.3, 128.2, 128.0, 127.6, 127.5, 127.3, 127.2, 116.1, 99.6, 83.0, 72.8, 69.8, 69.2, 62.0, 50.9, 18.9 HRMS (ESI-TOF) m/z: [M+Na] calcd for C<sub>29</sub>H<sub>30</sub>O<sub>4</sub>Na 465.2042, found 465.2045



(2*S*,3*R*,4*R*,5*S*,6*S*)-4-(allyloxy)-5-(benzyloxy)-3-iodo-6-methyltetrahydro-2*H*-pyran-2-yl acetate (42 $\alpha$ ) and (2*R*,3*R*,4*R*,5*S*,6*S*)-4-(allyloxy)-5-(benzyloxy)-3-iodo-6-methyltetrahydro-2*H*-pyran-2-yl acetate (42 $\beta$ ): ): Compounds 42 $\alpha$  and 42 $\beta$  were synthesized from 30 (700 mg, 2.63 mmol) by following general procedure A. 42 $\alpha$  yield: 580 mg, 50%, colorless gel. *R*<sub>f</sub> = 0.4 (10% EtOAc/hexane). 42 $\beta$  yield: 500 mg, 45%, colorless gel. *R*<sub>f</sub> = 0.35 (10% EtOAc/hexane).

#### Compound 42a:

<sup>1</sup>**H NMR** (**500 MHz, CDCl<sub>3</sub>**):  $\delta$  7.31-7.43 (m, 5H), 6.35 (d, 1H, *J* = 1.5 Hz), 5.97-6.04 (m, 1H), 5.39 (dq, 1H, J = 1.5 Hz, *J* = 17.5 Hz), 5.25 (dq, 1H, *J* = 1.5 Hz, *J* = 10.5), 4.97 (d, 1H, *J* = 10.5 Hz), 4.50 (dd, 1H, *J* = 1.5 Hz, *J* = 4 Hz), 4.20 (ddt, 1H, *J* = 1.5 Hz, *J* = 5.5 Hz, *J* = 12.5 Hz), 4.06 (ddt, 1H, *J* = 1 Hz, *J* = 5.5 Hz, *J* = 12.5 Hz), 3.89-3.95 (m, 1H), 3.53 (t, 1H, *J* = 9 Hz), 3.12 (q, 1H, *J* = 4.5 Hz), 2.09 (s, 3H), 1.35 (d, 3H, *J* = 6.5).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 168.7, 138.1, 134.2, 128.5, 128.2, 127.9, 117.7, 95.3, 81.1, 76.1, 75.6, 70.8, 70.1, 31.9, 20.9, 18.1.

**HRMS (ESI-TOF)** m/z: [M+Na] calcd for C<sub>18</sub>H<sub>23</sub>IO<sub>5</sub>Na 469.0488, found 469.0486. **Compound 42β:**  $[\alpha]_D^{25} = -51.9$  (*c* 2.13, CHCl<sub>3</sub>).

<sup>1</sup>**H NMR (500 MHz, CDCl<sub>3</sub>):**  $\delta$  7.33-7.37 (m, 5H), 5.98-6.06 (m, 1H), 5.78 (d, 1H, *J* = 9.5), 5.31 (d, 1H, *J* = 17.5 Hz), 5.20 (d, 1H, *J* = 10 Hz), 4.84 (d, 1H, *J* = 11 Hz), 4.63 (d, 1H, *J* = 10.5), 4.36-4.43 (m, 2H), 3.89 (t, 1H, *J* = 10 Hz), 3.53-3.60 (m, 2H), 3.16 (t, 1H, *J* = 9 Hz), 2.13 (s, 3H), 1.29 (d, 3H, *J* = 6 Hz).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 168.9, 137.6, 134.3, 128.5, 128.0, 117.5, 94.0, 85.1, 84.5, 75.4, 74.6, 72.5, 30.7, 20.8, 17.6.



(2*S*,3*S*,4*R*,5*R*,6*R*)-4-(allyloxy)-3-(benzyloxy)-5-iodo-2-methyl-6-(((3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methoxy)tetrahydro-2*H*-pyran

(44): To a stirred solution of donor sugar  $42\alpha$  (330 mg, 1.0 eq) and acceptor sugar 43 (376 mg, 1.1 eq) in anhydrous toluene (10 mL/mmol) under an inert atmosphere was added 4 Å molecular sieves and the solution was stirred for 20 min at room temperature. The reaction mixture was further cooled to 0 °C. TMSOTf (0.4 eq) was added dropwise to the above reaction mixture, and stirring was continued at 0 °C. After completion of the reaction (~20 min, monitored by TLC) triethylamine (0.6 mmol) at the same temperature to quench the reaction. The solvent was removed under reduced pressure to obtain the crude product, which was purified by column chromatography using hexane and ethyl acetate to obtain the glycosylated product 44 as a single diastereomer ( $\alpha$  only) in 80% (502.0 mg).  $[\alpha]_D^{25} = 40.8$  (c 1.13, CHCl<sub>3</sub>). <sup>1</sup>**H NMR (500 MHz, CDCl<sub>3</sub>):**  $\delta$  7.32-7.36 (m, 20H), 5.92-6.00 (m, 1H), 5.34 (dd, 1H, J = 1.5Hz, J = 17.5 Hz), 5.19 (dd, 1H, J = 1.0 Hz, J = 10.0 Hz), 5.00 (d, 1H, J = 11.5 Hz), 4.99 (bs, 1H), 4.93 (d, 1H, J = 11.0 Hz), 4.89 (d, 1H, J = 11.0 Hz), 4.82 (d, 1H, J = 10.5 Hz), 4.79 (d, 1H, J = 12.5 Hz), 4.67 (d, 1H, J = 12.0 Hz), 4.61 (d, 1H, J = 11.0 Hz), 4.54-4.57 (m, 2H), 4.34-4.35 (m, 1H), 4.11-4.15 (m, 1H), 3.97-4.01 (m, 2H), 3.77-3.80 (m, 2H), 3.69-3.72 (m, 1H), 3.50 (dd, 1H, J = 3.5 Hz, J = 13.5 Hz), 3.38-3.46 (m, 3H), 3.35 (s, 3H), 3.09 (dd, 1H, J = 4.0 Hz, *J* = 8.5 Hz), 1.27 (d, 3H, *J* = 6.5 Hz).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 138.6, 138.3, 138.0, 134.4, 128.4(3), 128.3 (2), 128.2(2), 128.0(2), 127.9, 127.8, 127.7, 127.6, 117.3, 101.3, 97.8, 82.1, 81.6, 80.0, 77.4, 76.3, 75.8, 75.4, 74.8, 73.3, 69.9, 69.8, 68.2, 66.4, 55.0, 34.3, 17.9

HRMS (ESI-TOF) *m/z*: [M+NH4] calcd for C44H51IO9NH4 868.2932, found 868.2932.



(2*S*,3*S*,6*R*)-4-(allyloxy)-3-(benzyloxy)-2-methyl-6-(((3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methoxy)-3,6-dihydro-2*H*-pyran (47): Compound 47 was synthesized from 44 (100 mg, 0.11 mmol) by following general procedure B. Yield: 80.7 mg, 97%, colorless gel.  $R_f = 0.5$  (20% EtOAc/hexane).  $[\alpha]_D^{25} = -23.2$  (*c* 0.52, CHCl<sub>3</sub>).

<sup>1</sup>**H NMR** (**500 MHz**, **CDCl**<sub>3</sub>):  $\delta$  7.30-7.38 (m, 20H), 5.98-6.05 (m, 1H), 5.40 (dd, 1H, J = 1.5 Hz, J = 17.5 Hz), 5.27 (dd, 1H, J = 1.5 Hz, J = 12.0 Hz), 5.03 (d, 1H, J = 4.0 Hz), 5.02 (d, 1H, 11.5 Hz), 4.94 (d, 1H, J = 11.0 Hz), 4.91 (d, 1H, J = 11.0 Hz), 4.84 (d, 1H, J = 11.0 Hz), 4.81 (d, 1H, J = 12.5 Hz), 4.69 (d, 1H, J = 4.0 Hz), 4.68 (d, 1H, J = 12.5 Hz), 4.59-4.61 (m, 3H), 4.30-4.34 (m, 1H), 4.23-4.27 (m, 1H), 4.08-4.13 (m, 1H), 4.03 (t, 1H, J = 9.0 Hz), 3.93 (dd, 1H, J = 2.0 Hz, J = 11.0 Hz), 3.76-3.79 (m, 1H), 3.74 (d, 1H, J = 9.0 Hz), 3.62 (dd, 1H, J = 5.0 Hz, J = 11.0 Hz), 3.51-3.57 (m, 2H), 3.39 (s, 3H), 1.26 (d, 3H, J = 6.5 Hz).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 157.5, 138.8, 138.5, 138.3, 138.2, 132.8, 128.4(3), 128.2, 128.1(2), 128.1, 127.9 (2), 127.8, 127.7, 127.6, 127.5, 117.5, 98.0, 96.2, 95.6, 82.1, 80.0, 77.9, 77.0, 75.7, 74.9, 74.0, 73.3, 70.1, 68.0, 66.5, 66.1, 55.1, 18.2

HRMS (ESI-TOF) *m/z*: [M+NH<sub>4</sub>] calcd for C<sub>44</sub>H<sub>50</sub>O<sub>9</sub>NH<sub>4</sub> 740.3799, found 740.3799.



(2R,3S,5S,6S)-3-allyl-5-(benzyloxy)-6-methyl-2-(((2R,3R,4S,5R,6S)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methoxy)tetrahydro-4*H*-pyran-4-one (48a) and (2R,3R,5S,6S)-3-allyl-5-(benzyloxy)-6-methyl-2-(((2R,3R,4S,5R,6S)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methoxy)tetrahydro-4*H*-pyran-4-one (48b) :

Compounds **48a** and **48b** were synthesized from **47** (70 mg, 0.09 mmol) by following general **procedure C.** Combine yield: 60.8 mg, 95%, colourless gel.  $R_f = 0.5$  (20% EtOAc/hexane).

Compound **48a**:  $[\alpha]_D^{25} = -20.3$  (*c* 0.30, CHCl<sub>3</sub>). <sup>1</sup>**H** NMR (**500** MHz, CDCl<sub>3</sub>):  $\delta$  7.30-7.35 (m, 20H), 5.61-5.69 (m, 1H), 5.04-5.08 (m, 1H), 5.04 (s, 1H), 4.98 (d, 1H, *J* = 11.0 Hz), 4.88 (dd, 2H, *J* = 3.0 Hz, *J* = 11.5 Hz), 4.78 (dd, 2H, *J* = 8.0 Hz, *J* = 10.5 Hz), 4.73 (s, 1H), 4.64 (d, 1H, J) = 10.5 Hz

*J* = 12.0 Hz), 4.52 (d, 1H, *J* = 2.0 Hz), 4.51 (d, 1H, *J* = 5.5 Hz), 4.45 (d, 1H, *J* = 11.5 Hz), 4.02-4.06 (m, 1H), 3.96 (t, 1H, *J* = 7.5 Hz), 3.78 (dd, 1H, *J* = 2.0 Hz, *J* = 11.0 Hz), 3.69-3.728 (m, 1H), 3.69 (d, 1H, *J* = 10.0 Hz), 3.48-3.50 (m, 2H), 3.43 (dd, 1H, *J* = 9.0 Hz, *J* = 10.0 Hz), 3.37 (s, 1H), 3.33 (s, 3H), 2.63 (t, 1H, *J* = 8.0 Hz), 2.31-2.39 (m, 2H), 1.30 (d, 3H, *J* = 6.5 Hz).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 206.1, 138.8, 138.3, 138.1, 137.4, 133.9, 128.5(2), 128.4(3), 128.2, 128.0, 128.0, 127.9, 127.8, 127.7, 127.6, 117.9, 101.4, 97.9, 82.1 (2), 80.1, 77.3, 75.7, 74.9, 73.5, 73.2, 69.7, 69.0, 66.2, 56.1, 55.1, 34.5, 18.8

HRMS (ESI-TOF) m/z: [M+NH4] calcd for C44H50O9NH4 740.3799, found 740.3797.

Compound **48b**:  $[\alpha]_D^{25} = -2.0 \ (c \ 0.10, \text{CHCl}_3)$ . <sup>1</sup>**H NMR (500 MHz, CDCl}3):**  $\delta$  7.25-7.37 (m, 20H), 5.64-5.72 (m, 1H), 4.98-5.0 (m, 2H), 4.97 (d, 1H, J = 10.7 Hz), 4.83- 4.86 (m, 2H), 4.81- 4.82 (m, 1H), 4.77-4.79 (m, 2H), 4.68 (t, 2H, J = 10.6 Hz), 4.59 (d, 1H, J = 3.5 Hz), 4.40 (d, 1H, J = 11.5 Hz), 4.21 (dd, 1H, J = 3.5 Hz, J = 11.5 Hz), 3.97 (t, 1H, J = 9.0 Hz), 3.7 (dd, 1H, J = 2.9, J = 9.9 Hz), 3.68 (d, 1H, J = 9.1 Hz), 3.60- 3.66 (m, 2H), 3.57 (t, 1H, J = 9.2 Hz), 3.50 (dd, 1H, J = 3.5, J = 9.5 Hz), 3.34 (s, 3H), 2.92-2.96 (m, 1H), 2.59-2.65 (m, 1H), 2.36-2.43 (m, 1H), 1.33 (d, 3H, J = 6.0 Hz).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): 206.8, 138.7, 138.3, 138.1, 137.2, 134.6, 128.5, 128.5, 128.4, 128.4(2), 128.1(4), 127.9, 127.8, 127.7, 117.2, 101.1, 98.2, 82.5, 82.0, 80.0, 77.6, 75.9, 75.2, 73.5, 73.2, 71.9, 69.9, 67.1, 56.1, 55.2, 29.6, 19.0.

HRMS (ESI-TOF) *m/z*: [M+NH<sub>4</sub>] calcd for C<sub>44</sub>H<sub>50</sub>O<sub>9</sub>NH<sub>4</sub> 740.3799, found 740.3794.



## (3a*R*,5a*S*,8a*S*,8b*R*)-3a-((((2*S*,3*R*,4*R*,5*S*,6*S*)-4-(allyloxy)-5-(benzyloxy)-3-iodo-6methyltetrahydro-2*H*-pyran-2-yl)oxy)methyl)-2,2,7,7-tetramethyltetrahydro-5*H*-

**bis**([1,3]dioxolo)[4,5-b:4',5'-d]pyran (46): To a stirred solution of donor sugar 42a (100 mg, 1.0 eq) and acceptor sugar 45 (64 mg, 1.1 eq) in anhydrous toluene (10 mL/mmol) under an inert atmosphere was added 4 Å molecular sieves and the solution was stirred for 20 min at rt. The reaction mixture was further cooled to 0 °C. TMSOTf (0.4 eq) was added dropwise to the above reaction mixture, and stirring was continued at 0 °C. After completion of the reaction

(monitored by TLC) it was quenched by triethylamine (0.6 mmol) at the same temperature. The solvent was removed under reduced pressure to obtain the crude product, which was purified by column chromatography using hexane and ethyl acetate to obtain the glycosylated product **46** as a single diastereomer ( $\alpha$  only) in 95% (137.5 mg) yield. [ $\alpha$ ]<sub>D</sub><sup>25</sup> = -18.4 (*c* 0.68, CHCl<sub>3</sub>).

<sup>1</sup>**H NMR** (**500 MHz, CDCl<sub>3</sub>**):  $\delta$  7.29-7.36 (m, 5H), 5.91-5.99 (m, 1H), 5.32 (dd, 1H, *J* = 1.5 Hz, *J* = 17.0 Hz), 5.22 (s, 1H), 5.18 (dd, 1H, *J* = 1.5 Hz, *J* = 10.5 Hz), 4.93 (d, 1H, *J* = 11.0 Hz), 4.63 (d, 1H, *J* = 10.5 Hz), 4.57 (dd, 1H, *J* = 2.5 Hz, *J* = 7.5 Hz), 4.52 (d, 1H, *J* = 4.0 Hz), 4.31 (d, 1H, *J* = 2.5 Hz), 4.21 (d, 1H, *J* = 8.0 Hz), 4.13-4.17 (m, 1H), 4.00-4.03 (m, 1H), 3.88 (dd, 1H, *J* = 1.5 Hz, *J* = 12.5 Hz), 3.76-3.79 (m, 1H), 3.72 (d, 1H, *J* = 13.0 Hz), 3.69 (d, 1H, *J* = 10.5 Hz), 3.56 (d, 1H, *J* = 11.0 Hz), 3.46 (t, 1H, *J* = 9.0 Hz), 3.08 (dd, 1H, *J* = 4.0 Hz, *J* = 8.5 Hz), 1.53 (s, 3H), 1.43 (s, 3H), 1.37 (s, 3H), 1.31 (s, 3H), 1.29 (d, 3H, *J* = 6.5 Hz).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 138.3, 134.4, 128.5, 128.3, 127.9, 117.6, 108.9, 108.5, 102.1, 101.6, 81.5, 76.5, 75.7, 70.9, 70.1, 69.9, 69.8, 68.7, 67.7, 61.1, 33.7, 26.6, 25.8, 25.4, 23.9, 17.8 HRMS (ESI-TOF) *m/z*: [M+Na] calcd for C<sub>28</sub>H<sub>39</sub>IO<sub>9</sub>Na 669.1536, found 669.1537.



(3aR,5aS,8aS,8bR)-3a-((((2R,5S,6S)-4-(allyloxy)-5-(benzyloxy)-6-methyl-5,6-dihydro-2H-pyran-2-yl)oxy)methyl)-2,2,7,7-tetramethyltetrahydro-5H-bis([1,3]dioxolo)[4,5b:4',5'-d]pyran (49): Compound 49 was synthesized from 46 (150 mg, 0.232 mmol) byfollowing general procedure**B** $. Yield: 116.6 mg, 95%, colureless gel. <math>R_f = 0.5$  (20% EtOAc/hexane).  $[\alpha]_D^{25} = -50.0$  (*c* 0.05, CHCl<sub>3</sub>).

<sup>1</sup>**H NMR (500 MHz, CDCl<sub>3</sub>):**  $\delta$  7.28-7.38 (m, 5H), 5.95-6.02 (m, 1H), 5.36 (dd, 1H, *J* = 1.5Hz, *J* = 17.5 Hz), 5.24 (dd, 1H, *J* = 1.5 Hz, *J* = 10.5 Hz), 5.14 (d, 1H, *J* = 3.5 Hz), 4.94 (d, 1H, *J* = 11.0 Hz), 4.76 (d, 1H, *J* = 3.0 Hz), 4.59 (d, 1H, *J* = 11.0 Hz), 4.56 (dd, 1H, *J* = 2.5 Hz, *J* = 8.0 Hz), 4.38 (d, 1H, *J* = 2.5 Hz), 4.20-4.32 (m, 3H), 4.00-4.06 (m, 1H), 3.90 (dd, 1H, *J* = 2.0 Hz, *J* = 13.0 Hz), 3.78 (d, 1H, *J* = 10.5 Hz), 3.75 (d, 1H, *J* = 9.0 Hz), 3.72 (d, 1H, *J* = 13.0 Hz), 3.62 (d, 1H, *J* = 10.5 Hz), 1.53 (s, 3H), 1.46 (s, 3H), 1.40 (s, 3H), 1.32 (s, 3H), 1.26 (d, 3H, *J* = 6.5 Hz).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 157.6, 138.3, 132.7, 128.3(3), 127.7, 117.5, 108.8, 108.4, 102.6, 95.7, 95.6, 76.7, 74.4, 71.0, 70.1, 70.0, 68.1, 66.2, 61.0, 26.6, 25.9, 25.5, 24.0, 18.0
HRMS (ESI-TOF) *m/z*: [M+Na] calcd for C<sub>28</sub>H<sub>38</sub>O<sub>9</sub>Na 541.2414, found 541.2419.



(2*R*,3*S*,5*S*,6*S*)-3-allyl-5-(benzyloxy)-6-methyl-2-(((3a*R*,5a*S*,8a*S*,8b*R*)-2,2,7,7tetramethyltetrahydro-3a*H*-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-3ayl)methoxy)tetrahydro-4*H*-pyran-4-one (50a) and (2*R*,3*R*,5*S*,6*S*)-3-allyl-5-(benzyloxy)-6methyl-2-(((3a*R*,5a*S*,8a*S*,8b*R*)-2,2,7,7-tetramethyltetrahydro-3a*H*-bis([1,3]dioxolo)[4,5b:4',5'-d]pyran-3a-yl)methoxy)tetrahydro-4*H*-pyran-4-one (50b): Compounds 50a:50b were synthesized from 49 (100 mg, 0.19 mmol) by following general procedure C. Combined

yield: 86.91 mg, 87%, colorless gel. *R<sub>f</sub>* = 0.5. (20% EtOAc/hexane). Compound **50a**: <sup>1</sup>**H NMR (500 MHz, CDCl<sub>3</sub>):** δ 7.32-7.39 (m, 5H), 5.65-5.73 (m, 1H), 5.11

Compound **50a**: <sup>1</sup>**H NMR (500 MHz, CDCI<sub>3</sub>):** 8 7.32-7.39 (m, 5H), 5.65-5.73 (m, 1H), 5.11 (s, 1H), 5.07-5.09(m, 1H), 4.94 (s, 1H), 4.91 (d, 1H, J = 12.0 Hz), 4.57(dd, 1H, J = 2.5 Hz, J = 8.0 Hz), 4.48 (d, 1H, J = 11.5 Hz), 4.34 (d, 1H, J = 3.0 Hz), 4.22 (d, 1H, J = 8.0 Hz), 3.98-4.03 (m, 1H), 3.92 (dd, 1H, J = 2.0 Hz, J = 12.9 Hz), 3.69-3.75 (m, 3H), 3.56 (d, 1H, J = 10.5 Hz), 2.75 (t, 1H, J = 6.5 Hz), 2.35-2.49 (m, 2H), 1.54 (s, 3H), 1.45 (s, 3H), 1.36-1.38(m, 6H), 1.33 (s, 3H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 206.2, 137.2, 133.6, 128.5, 128.4, 128.1, 118.0, 108.8, 108.7, 102.0, 101.5, 82.0, 73.2, 70.9, 69.8, 69.7, 69.6, 67.2, 61.0, 56.2, 34.4, 26.6, 25.8, 25.3, 23.9, 18.7.

HRMS (ESI-TOF) *m/z*: [M+Na] calcd for C<sub>28</sub>H<sub>38</sub>O<sub>9</sub>Na 541.2414, found 541.2419.

Compound **50b**: <sup>1</sup>**H NMR (500 MHz, CDCl<sub>3</sub>):**  $\delta$  7.32-7.41 (m, 5H), 5.73-5.81 (m, 1H), 5.11-5.17 (m, 1H), 5.07 (d, 1H, *J* = 10.1 Hz), 5.03 (d, 1H, *J* = 4.0 Hz), 4.95 (d, 1H, *J* = 11.5 Hz), 4.56 (dd, 1H, *J* = 2.5 Hz, *J* = 8.0 Hz), 4.50 (d, 1H, *J* = 11.5 Hz), 4.30 (d, 1H, *J* = 2.5 Hz), 4.22 (dd, 1H, *J* = 1.0 Hz, *J* = 8.0 Hz), 3.98-4.02 (m, 1H), 3.94 (dd, 1H, *J* = 1.5 Hz, *J* = 13.0 Hz), 3.77 (d, 1H, *J* = 10.0 Hz), 3.96-3.374 (m, 2H), 3.43 (d, 1H, *J* = 10.0 Hz), 2.75-2.79 (m, 1H), 2.49-2.55 (m, 1H), 2.25-2.32 (m, 1H), 1.54 (s, 3H), 1.45 (s, 3H), 1.40 (s, 3H), 1.36 (d, 3H, *J* = 6.5 Hz), 1.32 (s, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 204.0, 137.4, 134.9, 128.5, 128.4, 128.1, 117.4, 108.8, 108.8, 101.7, 100.7, 84.6, 73.1, 71.0, 70.4, 69.8, 69.5, 67.9, 61.0, 53.5, 27.9, 26.6, 25.9, 25.7, 23.8, 18.8.

**HRMS (ESI-TOF)** *m/z*: [M+NH<sub>4</sub>] calcd for C<sub>28</sub>H<sub>38</sub>O<sub>9</sub>NH<sub>4</sub> 536.2860, found 536.2863.



(2*S*,3*S*,4*S*)-4-(allyloxy)-2-methyl-3,4-dihydro-2H-pyran-3-ol (52): Compound 51 (3 g, 1eq) and Bu<sub>2</sub>SnO (6.3 g, 1.1 eq) were suspended in toluene at room temperature. The reaction mixture was stirred at reflux at 130 °C under Dean-Stark conditions for 6 h, then cooled to room temperature. The solvent was removed in vacuo. The resulting resulting solid CsF (7 g, 2 eq) was added and the mixture was suspended in THF, then allyl bromide (2.2 mL, 1.1 eq) was added at room temperature. The reaction mixture was stirred for 12 h, then imidazole (2.8 g, 1.8 eq) was added and allowed to stir for 1 h. The crude residue was filtered through a celite pad and washed with ethyl acetate and concentrated in vacuo. The crude residue was purified by flash column chromatography on silica gel. Yield: 2.3 g, 60%,  $R_f = 0.5$  (20% EtOAc/hexane).

<sup>1</sup>**H NMR (500 MHz, CDCl<sub>3</sub>):**  $\delta$  6.27 (dd, 1H, J = 1 Hz, J = 6 Hz), 5.85-5.92 (m, 1H), 5.25 (dq, 1H, J = 1.5 Hz, J = 17.5 Hz), 5.12-5.15 (m, 1H), 4.74 (dd, 1H, J = 2.5 Hz, J = 6.5 Hz), 4.09 (ddt, 1H, J = 1.5 Hz, J = 5.5 Hz, J = 13 Hz), 4.00 (ddt, 1H, J = 1.5 Hz, J = 5.5 Hz, J = 13 Hz), 3.93 (dt, 1H, J = 2 Hz, J = 7 Hz), 3.79-3.85 (m, 1H), 3.47-3.51 (m, 1H), 3.43 (bs, 1H), 1.32 (d, 3H, J = 6.5 Hz).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 144.8, 134.8, 117.1, 99.8, 76.7, 74.5, 72. 4, 69.3, 17.1.

HRMS (ESI-TOF) *m/z*: [M+Na] calcd for C<sub>9</sub>H<sub>14</sub>O<sub>3</sub>Na 193.0841, found 193.0839.



# (2*S*,3*S*,4*R*,5*R*,6*R*)-4-(allyloxy)-6-(benzyloxy)-5-iodo-2-methyltetrahydro-2*H*-pyran-3-ol (53): Compound 53 was synthesized from 52 (1g, 1eq) by following general procedure A. Yield: 1.8 g, 80%, colorless gel. $R_f = 0.5$ (20% EtOAc/hexane).

<sup>1</sup>**H NMR (500 MHz, CDCl<sub>3</sub>):**  $\delta$  7.33-7.41 (m, 5H), 5.95-6.03 (m, 1H), 5.37 (dd, 1H, *J* = 1.5 Hz, *J* = 17.5 Hz), 5.25-5.27 (m, 2H), 4.72 (d, 1H, *J* = 6 Hz), 4.50-4.53 (m, 2H), 4.15 (ddt, 1H, *J* = 1.5 Hz, *J* = 6 Hz, *J* = 12.5 Hz), 3.86-3.90 (m, 1H), 3.91-3.96 (m, 1H), 3.65 (t, 1H, *J* = 9.5), 3.03 (dd, 1H, *J* = 4 Hz, *J* = 9 Hz), 2.73 (bs, 1H), 1.38 (d, 3H, *J* = 6 Hz).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 137.0, 133.9, 128.5, 128.4, 127.8, 118.1, 101.0, 76.1, 73.5, 69.5 (2), 68.9, 32.6, 17.8.

**HRMS (ESI-TOF)** *m/z*: [M+Na] calcd for C<sub>16</sub>H<sub>21</sub>IO<sub>4</sub>Na 427.0382, found 427.0380.



## (2*R*,3*R*,4*R*,6*S*)-4-(allyloxy)-2-(benzyloxy)-5-(((2*R*,4*R*,5*S*,6*R*)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2*H*-pyran-2-yl)oxy)-3-iodo-6-methyltetrahydro-2*H*-

**pyran (55):** To a stirred solution of donor sugar **54** (200 mg, 1.0 eq) and acceptor sugar **53a** (186.63 mg, 1.1 eq) in anhydrous toluene (10 mL/mmol) under an inert atmosphere was added 4 Å molecular sieves and the solution was stirred for 20 min at rt. The reaction mixture was further cooled to 0 °C. TMSOTf (0.4 eq) was added dropwise to the above reaction mixture, and stirring was continued at 0 °C. The reaction was monitored by TLC and quenched by triethylamine (0.6 mmol) at the same temperature and allowed to room temperature. The solvent was removed under reduced pressure to obtain the crude product, which was purified by column chromatography using hexane and ethyl acetate to obtain the glycosylated product **55** of as a single diastereomer ( $\alpha$  only) in 80% (274.9 mg) yield.

<sup>1</sup>**H NMR** (**500 MHz**, **CDCl**<sub>3</sub>):  $\delta$  7.23-7.38 (m, 20H), 5.90-5.98 (m, 1H), 5.28-5.32 (m, 1H), 5.23 (d, 1H, J = 1.5 Hz), 5.18 (d, 1H, J = 3.0 Hz), 5.15 (dd, 1H, J = 1.5 Hz, J = 10.0 Hz ), 4.91 (d, 1H, J = 11.0 Hz), 4.68-4.72 (m, 4H), 4.58 (d, 1H, J = 11.0 Hz), 4.53 (dd, 1H, J = 1.5 Hz, J = 4.0 Hz), 4.51 (d, 1H, J = 6.0 Hz), 4.49 (d, 1H, J = 6.0 Hz), 4.14-4.17 (m, 1H), 4.01-4.06 (m, 1H), 3.91-3.98 (m, 2H), 3.85 (dd, 1H, J = 6.5 Hz, J = 9.0 Hz), 3.81 (dd, 1H, J = 3.0 Hz, J = 10.5 Hz ), 3.67-3.74 (m, 3H), 3.08 (dd, 1H, J = 4.0 Hz, J = 8.5 Hz ), 2.27-2.31(m, 1H), 1.73-1.79 (m, 1H), 1.31 (d, 3H, J = 6.5 Hz).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 138.9, 138.7, 138.3, 137.0, 134.2, 128.5, 128.3, 128.2, 128.2(2), 127.9 (2), 127.6 (2), 127.5 (2), 127.3, 117.8, 100.5, 97.9, 78.4, 78.2, 77.3, 75.2, 74.7, 73.4, 71.8, 71.0, 69.9, 69.5, 68.9, 68.9, 35.5, 33.9, 18.3

**HRMS** (**ESI-TOF**) *m/z*: [M+NH<sub>4</sub>] calcd for C<sub>43</sub>H<sub>49</sub>IO<sub>8</sub>NH<sub>4</sub> 838.2816, found 838.2816.



(2*S*,3*S*,6*R*)-4-(allyloxy)-6-(benzyloxy)-3-(((2*R*,4*R*,5*S*,6*R*)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2*H*-pyran-2-yl)oxy)-2-methyl-3,6-dihydro-2*H*-

**pyran(58):** Compound **58** was synthesized from **55** (170 mg, 0.20 mmol) by following **general procedure B**. Yield: 133.4 mg, 93%, colorless gel.  $R_f = 0.5$  (20% EtOAc/hexane).

<sup>1</sup>**H NMR** (**500 MHz, CDCl<sub>3</sub>**):  $\delta$  7.20-7.37 (m, 20H), 5.89-5.94 (m, 1H), 5.30 (dd, 1H, *J* = 1.0 Hz, *J* = 17.0 Hz ), 5.17-5.20 (m, 2H), 5.09 (d, 1H, *J* = 3.0 Hz), 4.90 (d, 1H, *J* = 11.0 Hz), 4.78 (d, 1H, *J* = 2.5 Hz), 4.75 (d, 1H, *J* = 12.0 Hz), 4.65-4.67 (m, 3H), 4.58 (d, 1H, *J* = 12.5 Hz), 4.56 (d, 1H, *J* = 12.5 Hz), 4.48 (d, 1H, *J* = 12.5 Hz), 4.19-4.26 (m, 4H), 3.96-4.00 (m, 2H), 3.79 (dd, 1H, *J* = 3.0 Hz, *J* = 10.5 Hz ), 3.69 (t, 1H, *J* = 9.5 Hz), 3.61 (dd, 1H, *J* = 1.5 Hz, *J* = 10.5 Hz), 2.30 (dd, 1H, *J* = 5.0 Hz, *J* = 12.0 Hz), 1.74 (td, 1H, *J* = 3.5 Hz, *J* = 12.5 Hz ), 1.25 (d, 3H, *J* = 6.5 Hz).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 155.7, 139.0, 138.8, 138.4, 138.3, 132.6, 128.4 (2), 128.3, 128.2, 128.0, 127.9, 127.6, 127.6(2), 127.5 (2), 127.4, 118.5, 97.9, 96.9, 95.1, 78.3, 77.5, 75.9, 74.6, 73.5, 72.0, 71.3, 69.6, 69.0, 68.5, 67.0, 35.9, 18.4

**HRMS (ESI-TOF)** *m/z*: [M+NH<sub>4</sub>] calcd for C<sub>43</sub>H<sub>48</sub>O<sub>8</sub>NH<sub>4</sub> 710.3693, found 710.3693.



(2R,3S,5S,6S)-3-allyl-2-(benzyloxy)-5-(((2R,4R,5S,6R)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2*H*-pyran-2-yl)oxy)-6-methyltetrahydro-4*H*-pyran-4one (59a) and (2R,3R,5S,6S)-3-allyl-2-(benzyloxy)-5-(((2R,4R,5S,6R)-4,5-bis(benzyloxy)-

# 6-((benzyloxy)methyl)tetrahydro-2*H*-pyran-2-yl)oxy)-6-methyltetrahydro-4*H*-pyran-4one (59b): Compounds 59a:59b were synthesized from 58 (100 mg, 0.14 mmol) by following general procedure C. Obtained as an inseparable mixture. Combined yield: 86.65 mg, 87%, colorless gel. $R_f = 0.5$ (20% EtOAc/hexane).

**Compound 59a** (selected data for the major product): <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  7.25-7.36 (m, 20H), 5.59-5.67 (m, 1H), 5.06 (dd, 1H, J = 1.0 Hz, J = 17.0 Hz ), 4.96-4.99 (m, 2H), 4.89 (d, 2H, J = 11.0 Hz), 4.65-4.67 (m, 3H), 4.59 (d, 1H, J = 12.0 Hz), 4.54 (d, 1H, J = 11.0 Hz), 4.48 (d, 1H, J = 12.5 Hz), 4.44 (d, 1H, J = 12.0 Hz), 4.33-4.36 (m, 1H), 4.03-4.10 (m, 2H), 3.96 (d, 1H, J = 9.5 Hz), 3.78 (dd, 1H, J = 3.0 Hz, J = 13.5 Hz ), 3.66 (t, 1H, J = 9.5 Hz), 3.49 (dd, 1H, J = 2.0 Hz, J = 10.5 Hz ), 2.71 (t, 1H, J = 8.0 Hz), 2.33-2.43 (m, 3H), 1.74-1.80 (m, 1H), 1.33 (d, 3H, J = 6.0 Hz).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 204.2, 138.9, 138.8, 138.2, 137.0, 133.8, 128.4, 128.4, 128.3, 128.2, 127.9, 127.8, 127.8, 127.7, 127.6, 127.6, 127.5, 127.4, 117.8, 100.6, 99.5, 82.0, 78.2, 77.5, 74.6, 73.4, 72.2, 71.4, 69.8, 69.1, 68.6, 56.4, 35.6, 34.4, 18.6

**HRMS** (**ESI-TOF**) *m/z*: [M+NH<sub>4</sub>] calcd for C<sub>43</sub>H<sub>48</sub>O<sub>8</sub>NH<sub>4</sub> 710.3693, found 710.3695.



(((3*R*,4*S*,6*S*)-6-(((2*S*,4*R*,5*R*,6*R*)-4-(allyloxy)-6-(benzyloxy)-5-iodo-2-methyltetrahydro-2*H*-pyran-3-yl) oxy)tetrahydro-2*H*-pyran-3,4-diyl)bis(oxy))bis(tert-butyldimethylsilane) (57): To a stirred solution of donor sugar 56 (100 mg, 1.0 eq) and the acceptor sugar 53 $\alpha$  (135.9 mg, 1.2 eq) in anhydrous toluene (10 mL/mmol) under an inert atmosphere was added 4 Å molecular sieves and the solution was stirred for 1 h. Ph<sub>3</sub>P·HBr (0.8 eq) was added to the abovestirred solution, and stirring was continued for 3 h. After the complete consumption of the starting material, the solvent was concentrated under reduced pressure to obtain the crude product, which was purified by column chromatography using hexane and ethyl acetate to obtain the glycosylated product 57 as a single diastereomer ( $\beta$  only) in 90% (201.0 mg) yield. [ $\alpha$ ]<sub>D</sub><sup>25</sup> = -50.6 (*c* 0.73, CHCl<sub>3</sub>).

<sup>1</sup>**H** NMR (**500** MHz, CDCl<sub>3</sub>):  $\delta$  7.29-7.37 (m, 5H), 5.89-5.93 (m, 1H), 5.28-5.31 (m, 1H), 5.16-5.19 (m, 3H), 4.67 (d, 1H, J = 11.5 Hz), 4.45-4.48 (m, 2H), 4.05-4.09 (m, 1H), 3.97-4.00 (m, 1H), 3.89-3.93 (m, 1H), 3.76-3.81 (m, 1H), 3.69-3.71 (m, 1H), 3.60-3.66 (m, 4H),

3.08 (dd, 1H, *J* = 4.0 Hz, *J* = 8.5 Hz ), 2.01-2.06 (m, 1H), 1.34 (d, 3H, *J* = 6.5 Hz), 0.90 (s, 9H), 0.89 (s, 9H), 0.06-0.07 (m, 12H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 137.1, 134.4, 128.5, 128.0(2), 117.4, 100.7, 99.6, 79.3, 76.3, 70.0, 69.6, 69.4, 68.3, 68.1, 68.0, 64.8, 33.8, 26.0 (2), 18.3 (2), 18.2, -4.4 (2), -4.7, -4.8 HRMS (ESI-TOF) *m/z*: [M+NH<sub>4</sub>] calcd for C<sub>33</sub>H<sub>57</sub>IO<sub>7</sub>Si<sub>2</sub>NH<sub>4</sub> 766.3031, found 766.3029



(((3R,4S,6S)-6-(((2S,6R)-4-(allyloxy)-6-(benzyloxy)-2-methyl-3,6-dihydro-2H-pyran-3-yl)oxy)tetrahydro-2H-pyran-3,4-diyl)bis(oxy))bis(tert-butyldimethylsilane)(60):Compound 60 was synthesized from 57 (200 mg, 0.285 mmol) by following general procedureB. Yield: 147.1 mg, 90%, colorless gel.  $R_f = 0.6$  (10% EtOAc/hexane).

<sup>1</sup>**H** NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  7.29-739 (m, 5H), 5.90-5.98 (m, 1H), 5.30 (dd, 1H, J = 1.5 Hz, J = 17.5 Hz ), 5.20-5.24 (m, 3H), 4.76 (d, 1H, J = 11.5 Hz), 4.72 (d, 1H, J = 3.5 Hz), 4.58 (d, 1H, J = 12.0 Hz), 4.21-4.30 (m, 2H), 4.03-4.07 (m, 1H), 3.99-4.02 (m, 1H), 3.93 (d, 1H, J = 9.0 Hz), 3.69-3.74 (m, 2H), 3.65 (dd, 1H, J = 6.0 Hz, J = 11.0 Hz), 2.04-2.09 (m, 1H), 1.64-1.69 (m, 1H), 1.32 (d, 3H, J = 6.5 Hz), 0.92 (s, 9H), 0.91 (s, 9H), 0.07-0.09 (m, 12H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ157.6, 138.4, 132.8, 128.4(2), 128.0(2), 127.5, 117.6, 99.9, 95.2, 95.2, 75.2, 70.1, 69.6, 68.1, 68.0, 66.5, 64.8, 26.0, 26.0, 18.4, 18.3, 18.2, -4.4 (2), -4.7, -4.8

HRMS (ESI-TOF) *m/z*: [M+NH4] calcd for C<sub>33</sub>H<sub>56</sub>O<sub>7</sub>Si<sub>2</sub>NH4 638.3908, found 638.3908.



#### (2R,3S,5S,6S)-3-allyl-2-(benzyloxy)-5-(((2S,4S,5R)-4,5-bis((tert-

butyldimethylsilyl)oxy)tetrahydro-2*H*-pyran-2-yl)oxy)-6-methyltetrahydro-4*H*-pyran-4one (61a) and (2*R*,3*R*,5*S*,6*S*)-3-allyl-2-(benzyloxy)-5-(((2*S*,4*S*,5*R*)-4,5-bis((*tert*butyldimethylsilyl)oxy)tetrahydro-2*H*-pyran-2-yl)oxy)-6-methyltetrahydro-4*H*-pyran-4one (61b): Compounds 61a and 61b were synthesized from 60 (100 mg, 0.61 mmol) by following general procedure C. Obtained as an inseparable mixture. Combined yield: 89.9 mg, 90%, colorless gel.  $R_f = 0.5$  (10% EtOAc/hexane).  $[\alpha]_D^{25} = -80.0$  (*c* 0.13, CHCl<sub>3</sub>).

**Compound 61a** (selected data for the major compound): <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.27-7.34 (m, 5H), 5.60-5.68 (m, 1H), 5.08 (dd, 1H, *J* = 1.5 Hz, *J* = 17.0 Hz ), 5.03-5.05 (m, 1H), 4.95-4.98 (m, 1H), 4.90 (s, 1H), 4.66 (d, 1H, *J* = 12.0 Hz), 4.48 (d, 1H, *J* = 12.0 Hz), 3.99-4.08 (m, 3H), 3.71-3.75 (m, 1H), 3.64 (dd, 1H, *J* = 2.5 Hz, *J* = 11.5 Hz), 3.58 (dd, 1H, *J* = 6.0 Hz, *J* = 11.5 Hz), 2.92-2.95 (m, 1H), 2.71 (t, 1H, *J* = 8.0 Hz), 2.37-2.45 (m, 1H), 2.12-2.17 ( m, 1H), 1.71-1.77(m, 1H), 1.39 (d, 3H, *J* = 6.0 Hz), 0.89 (s, 9H), 0.89 (s, 9H), 0.06-0.08 (m, 12H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 205.8, 137.1, 133.7, 128.4, 127.8, 127.7, 117.8, 100.6, 97.9, 79.2, 69.9, 69.2, 69.0, 67.6, 65.2, 56.1, 34.3, 25.9, 19.0, 18.2, 18.2, -4.4, -4.5, -4.7, -4.8.
HRMS (ESI-TOF) *m/z*: [M+NH<sub>4</sub>] calcd for C<sub>33</sub>H<sub>56</sub>O<sub>7</sub>Si<sub>2</sub>NH<sub>4</sub> 638.3908, found 638.3906.



(1*S*,3*R*,4*R*,4a*S*,7a*R*)-1,4-bis(benzyloxy)-3-((benzyloxy)methyl)-3,4,7,7atetrahydrocyclopenta[c]pyran-4a(1*H*)-ol (63a) and (1*S*,3*R*,4*R*,4a*R*,7a*R*)-1,4bis(benzyloxy)-3-((benzyloxy)methyl)-3,4,7,7a-tetrahydrocyclopenta[c]pyran-4a(1*H*)-ol (63b): To a stirred solution containing diastereomeric mixture of 13a: 13b (100 mg, 0.21 mmol) in dry THF (5 mL) at 0 °C was added vinyl magnesium bromide (0.5 mL, 0.42 mmol). The reaction mixture was allowed to come to room temperature and stirred for 3 h. After completion of the reaction, it was quenched by addition of saturated NH<sub>4</sub>Cl solution. The layers were separated and the aqueous layer was extracted with ethyl acetate. The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and filtered to obtain the crude mixture which was subjected to flash column chromatography to obtain an inseparable mixture of diastereomers **62** (70 mg, 67%) as a colorless gel.  $R_f = 0.6$  (20% EtOAc/hexane).

The diastereomeric mixture **62** (60 mg, 0.11 mmol) was dissolved in dichloromethane (2 mL) and to this Grubbs II<sup>nd</sup> generation catalyst (18.6 mg, 0.023 mmol) was added. The mixture was stirred at room temperature. After 5 h the solution was made into a slurry and column chromatography over silica gel provided compounds **63a** (17 mg, Yield:30%) as a colourless gel.  $R_f = 0.4$  (20% EtOAc/hexane) [ $\alpha$ ]\_D<sup>25</sup> = 67.2 (*c* 0.13, CHCl<sub>3</sub>).

and **63b** (31.1 mg, Yield: 55%), as a colourless gel.  $R_f = 0.45$  (20% EtOAc/hexane).  $[\alpha]_D^{25} = 94.6$  (*c* 0. 07, CHCl<sub>3</sub>).

Compound **63a** : <sup>1</sup>**H NMR** (**500 MHz**, **CDCl**<sub>3</sub>): δ 7.27-7.37 (m, 15H), 6.00-6.07 (m, 2H, H-8 & H-9), 5.19 (d, 1H, *J* = 3.0 Hz, H-1), 4.81 (d, 1H, *J* = 12.0 Hz), 4.65 (d, 2H, *J* = 12.0 Hz), 4.58 (d, 1H, *J* = 11.5 Hz), 4.56 (d, 1H, *J* = 12.0 Hz), 4.55 (d, 1H, J = 12.0 Hz) 4.53 (bs, 1H), 4.11 (m, 1H), 3.84 (dd, 1H, *J* = 3.5 Hz, *J* = 10.5 Hz, H-5), 3.75 (dd, 1H, *J* = 2.0 Hz, *J* = 10.5 Hz, H-6), 3.71 (d, 1H, J = 10.0 Hz, H-4), 2.57-2.63 (m, 1H, H-7a), 2.22-2.27 (m, 1H, H-7b), 2.08-2.12 (m, 1H, H-2).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 138.1, 136.9, 135.7, 134.7, 128.4 (2), 128.3, 128.2, 127.9(2), 127.8(2), 127.7, 127.6, 98.5, 81.2, 78.4, 73.7, 73.4, 70.0, 69.9, 68.9, 49.2, 30.1.

**HRMS** (**ESI-TOF**) *m/z*: [M+NH<sub>4</sub>] calcd for C<sub>30</sub>H<sub>32</sub>O<sub>5</sub>NH<sub>4</sub> 490.2593, found 490.2594.

Compound **63b** : <sup>1</sup>H NMR (**500** MHz, CDCl<sub>3</sub>):  $\delta$  7.21-7.36 (m, 15H), 5.77-5.82 (m, 2H, H-8 & H-9), 4.92 (s, 1H, H-1), 4.74 (d, 1H, *J* = 12.0 Hz), 4.66 (d, 1H, *J* = 12.5 Hz), 4.51-4.59 (m, 4H), 4.04-4.06 (m, 1H), 3.74 (dd, 1H, *J* = 4.0, 11.0 Hz, H-5), 3.64 (dd, 1H, *J* = 2.0 Hz, *J* = 11.0 Hz, H-6), 3,59 (d, 1H, *J* = 10.0 Hz, H-4), 3.07 (bs, 1H), 2.43-2.54 (m, 2H, H-2 & H-7a), 2.23-2.29 (m, 1H, H-7b).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 138.4, 138.1, 137.9, 137.7, 130.3, 128.5, 128.4, 128.3, 128.3, 128.0, 128.0, 127.9, 127.6, 127.5, 97.6, 82.2, 78.6, 74.8, 73.6, 69.1, 68.8, 65.1, 50.6, 33.9.





(1*R*,3*S*,4*S*,4*aR*,7*aR*)-1,4-bis(benzyloxy)-3-methyl-3,4,7,7a tetrahydrocyclopenta[c]pyran-4a(1*H*)-ol (65): To a stirred solution containing diastereomeric mixture of 33a: 33b (100 mg, 0.27 mmol) in dry THF (5 mL) at 0 °C was added vinyl magnesium bromide (0.7 mL, 0.54 mmol). The reaction mixture was allowed to come to room temperature and stirred for 3 h. After completion of the reaction, it was quenched by addition of saturated NH<sub>4</sub>Cl solution. The layers were separated and the aqueous layer was extracted with ethyl acetate. The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and filtered to obtain the crude mixture which was subjected to flash column chromatography to obtain an inseparable mixture of diastereomers **64** (86 mg, 80%) as a colorless gel.  $R_f = 0.6$  (5% EtOAc/hexane).

The diastereomeric mixture **64** (70 mg, 0.17 mmol) was dissolved in dichloromethane (3 mL) and to this Grubbs II<sup>nd</sup> generation catalyst (29.7 mg, 0.035 mmol) was added. The mixture was stirred at room temperature. After 5 h the solution was made into a slurry and column chromatography over silica gel provided compound **65** (32.5 mg, 50%), as a colourless gel.

 $R_f = 0.5$  (10% EtOAc/hexane).

<sup>1</sup>**H NMR** (**500 MHz**, **CDCl**<sub>3</sub>):  $\delta$  7.26-7.37 (m, 10H), 5.86-5.87 (m, 1H, H-9), 5.79-5.87 (m, 1H, H-8), 4.81 (s, 1H, H-1), 4.72 (d, 1H, *J* = 12.5 Hz), 4.66 (d, 1H, *J* = 11.5 Hz), 4.63 (d, 1H, *J* = 11.0 Hz), 4.55 (d, 1H, *J* = 12.5 Hz), 4.00-4.05 (m, 1H, H-5), 3.13 (d, 1H, *J* = 10.0 Hz, H-4), 3.08 (bs, 1H), 2.50-2.54 (m, 1H, H-2), 2.44-2.49 (m, 1H, H-7a), 2.18-2.24 (m, 1H, H-7b), 1.24 (d, 3H, *J* = 6.5 Hz, H-6).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 138.7, 137.9, 137.6, 130.2, 128.5, 28.4, 128.1, 128.0, 128.0, 127.6, 97.2, 84.8, 82.1, 75.3, 68.8, 61.4, 50.8, 34.0, 17.7.
HRMS (ESI-TOF) *m/z*: [M+Na] calcd for C<sub>23</sub>H<sub>26</sub>O<sub>4</sub>Na 389.1729, found 389.1728.

#### **References:**

- Colgan, A. C., Muller-Bunz, H. and McGarrigle, E. M., Benzylation Reactions in DMF Lead to an Impurity Which Acts as an Organocatalyst Poison in Thiourea-Catalyzed Glycosylations, *J. Org. Chem.*, 2016, **81**, 11394-11396.
- Kalikanda, J. and Li, Z., Study of the stereoselectivity of 2-azido-2-deoxygalactosyl donors: remote protecting group effects and temperature dependency, *J.Org. Chem.*, 2011, 76, 5207-5218.






















— 157.72	138.35 138.22 138.15 132.71 128.30 128.00 128.00 128.01 127.85 117.49	95.35 95.35 77.00 76.75 74.04 71.10 69.74 68.12 68.12	
BnO <sup>VV</sup> OBn			
<sup>13</sup> C{ <sup>1</sup> H} NMR (125 MHz,CD)	CI <sub>3</sub> )		
	·····		

210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0

ppm



























200	190	180	170		150	140	130	120	110	100	90		<b>.</b>	<b>60</b>	<b>50</b>	40	<b>.</b>	2	<b>0</b>	10	<b>0</b>	ppm
	<sup>13</sup> C{	BnO BnO	15 IR (125	MHz,C	DCI <sub>3</sub> )																	
					/ 138.38	13/.53 136.93 128.43	128.28	127.97	120.56	100.71	[77.25	76.51 75.85	72.19	65.34 65.34			34.03					









210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0	ppr
--	-----







































































































line

BnO

\_O<sub></sub> \_OBn

<sup>24</sup>4

 $\sim$ 



18.00





<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)









































	— 157.63			$\bigwedge_{102.62}^{108.83} - 102.62$	77.25 77.06 77.00 76.75 74.36 71.00 70.10 68.06 66.19 60.98	26.58 25.47 25.47 18.03	
<sup>13</sup> C{ <sup>1</sup> H} NMR, (125 MHz, CDCl <sub>3</sub> )							
200 190 180 170 16	50 <b>15</b> 0	140 130 1	20 1	10 100 9	0 80 70 60 5	0 40 30 20 10	0 ppm








































































